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Abstract 
Chronic wounds present a significant burden to patients, causing pain, impairing limb 
function, and often resulting in the need for amputation. Treatment of chronic dermal wounds 
is challenging, with current therapies showing limited efficacy in clinical trials.  As galectin-
3 has been implicated in several wound healing processes, its efficacy as a therapeutic in skin 
healing was investigated in this study. An electrospun gelatin scaffold loaded with galectin-3 
was developed as a delivery system. The influence of human recombinant galectin-3 in skin 
healing, when delivered topically and using an electrospun scaffold, was then investigated in 
wild type and diabetic mice. Electrospun gelatin/galectin-3 scaffolds were developed having 
an overall porosity of approximately 83% and average pore diameter of approximately 1.15 
μm. The scaffolds supported the adhesion, deposition of matrix, and proliferation of human 
dermal fibroblasts in vitro providing evidence that they are biocompatible. In vivo treatment 
of wounds with topical galectin-3 and gelatin/galectin-3 scaffolds did not affect wound 
closure, re-epithelialization or macrophage phenotypes in the wound, casting doubt on its 
efficacy for these processes. Future work is required to elucidate the exact pathological 
contexts in which galectin-3 might modulate inflammation in skin healing. 
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1 Introduction 
1.1 Skin, Cutaneous Wound Healing and Chronic Wounds 
1.1.1 Skin Anatomy and Physiology 
Skin is the largest organ in the human body, playing several important physiological roles 
including water regulation, thermoregulation as well as acting as a barrier against 
physical, chemical and biologic stresses (1, 2). Human skin is subdivided into three 
layers: the epidermis, dermis and the hypodermis. The epidermis is the outermost layer 
and is responsible for the skin’s barrier function. It is a cell dense layer consisting of 
keratinocytes that synthesize the major structural protein found in the epidermis, keratin. 
Also present in the epidermis are melanocytes, which produce melanosomes containing 
melanin, giving skin its pigmentation and providing protection for cell nuclei from 
ultraviolet light. Langerhans cells are also found in this layer and act as antigen-
presenting cells (3). The dermis is the largest layer of the skin and is responsible for 
protecting the body from mechanical injury (1, 4). The main structural component of 
dermis is the extracellular matrix (ECM), which consists of proteins including reticulin, 
elastin, and collagen (types I, III and V) (5). Collagen accounts for the majority of the 
ECM and is responsible for the elastic and tensile properties of skin (4). The primary cell 
type of the dermis is the fibroblast which acts to secrete ECM proteins (4). Upon reaction 
to different stimuli, various leukocyte populations including macrophages can enter the 
dermis through vascular networks (1). The subcutaneous tissue consists of lipocytes 
separated by fibrous septa containing blood vessels and collagen, and plays a role in 
buoyancy and providing energy storage (5). 
1.1.2 Cutaneous Wound Healing 
Normal cutaneous wound repair involves four overlapping phases of hemostasis, 
inflammation, proliferation, and remodeling. Upon injury, the inflammatory phase is 
initiated, with platelets aggregating in the wall of injured blood vessel to form a plug and 
subsequently a fibrin network. This creates a clot to establish homeostasis (6). 
Neutrophils are then recruited to debride the wound of foreign particles and bacteria. 
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Neutrophil populations are removed from the eschar or become engulfed by 
macrophages. In response to certain chemoattractants, including transforming growth 
factor beta (TGF-β), monocytes infiltrate the wound and differentiate into macrophages 
(7). Macrophages are central to development of  granulation tissue and are responsible for 
producing nitric oxide, pro-inflammatory cytokines such as tissue necrosis factor alpha 
(TNF-α), interleukin 1 beta (IL-1β), IL-6, and IL-12, and growth factors including 
fibroblast growth factor (FGF), epidermal growth factor (EGF), TGF-β, and platelet 
derived growth factor (PDGF) (8, 9).  
Within hours of initial injury, epithelial cell proliferation and migration is initiated 
through the release of EGF, transforming growth factor alpha (TGF-α) and FGF, which 
begins the re-epithelialization phase (9). The epidermis and the basement membrane 
separate via dissolution of their hemidesmosomal links and subsequent keratinocyte 
migration over the dermis separates the eschar from viable tissue (6, 7). Behind the 
leading edge of migration, the keratinocytes proliferate and mature, eventually restoring 
the barrier function of the epithelium (6). Macrophages secrete TGF-β that signals 
fibroblasts to migrate into the granulation tissue and produce new ECM components. 
These components, including fibronectin, hyaluoronic acid, and collagen, serve as a 
scaffold for cell infiltration of the granulation tissue through cell migration (7). The 
secretion of vascular endothelial growth factor (VEGF) and PDGF by activated platelets 
and macrophages initiates angiogenesis (6, 9). This process results in the formation of 
blood vessels that support the newly formed granulation tissue by providing a nutrient 
and oxygen supply to sustain cell growth and metabolism (7). TGF-β also stimulates the 
differentiation of fibroblasts into myofibroblasts, highly contractile cells which contract 
the wound, pulling the edges together to achieve closure (6, 9).   
During the remodeling phase endothelial cells, macrophages, and myofibroblasts undergo 
apoptosis or exit the wound. The wound consists predominantly of a type III collagen, 
ECM proteins and is largely acellular. It is subsequently remodeled into a type I collagen 
matrix by matrix metalloproteinases (MMPs) secreted by fibroblasts, macrophages, and 
endothelial cells, although the remodeled tissue never fully regains the tensile strength of 
the original skin (6, 7). 
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1.1.3 Chronic Dermal Wounds 
A dermal wound is classified as chronic if it has failed to progress through the normal 
sequences of the wound healing process within a twelve week period (10), resulting in 
the impairment of normal tissue function and anatomy (11). Chronic wounds are 
characterized by residual inflammation, cellular senescence, lack of cell signaling, and 
bacterial colonization (11). A variety of factors can contribute to their development, 
including vascular insufficiency, diabetes, malnutrition, patient age, pressure, infection, 
and edema (12). These wounds become a significant burden to the patient, as they can be 
painful, impair limb function, and result in sepsis or the need for amputation (12). 
Furthermore, they pose a significant burden to the Canadian healthcare system, with the 
average cost of treatment of a chronic wound being $10,376 (13). The most common 
types of chronic wounds, which include venous, arterial, and diabetic foot ulcers (DFUs), 
are discussed below (11, 14).  
Venous ulcers affect around 0.1% of the Canadian population. They are more common in 
older patients although early onset can begin in patients in their twenties (15). The skin in 
these patients becomes injured as a result of limb edema and venous hypertension, which 
can occur due to venous thrombosis, venous valve reflux, or from damage to the venous 
wall or valves (16, 17). The ulcers develop in the gaiter region of the lower leg, form with 
an irregular border, and usually contain granulation and fibrinous tissue. Patients 
typically experience aching of the legs after long periods of standing in addition to leg 
heaviness and swelling (11). 
Up to 10% of patients with lower limb ulcers have arterial insufficiency (18). Arterial 
ulcers can result from any process that obstructs arterial flow, which includes vasculitis, 
microthrombotic disease, sickle cell disease, and atherosclerosis. Progressive 
atherosclerosis is the most common cause for arterial ulcers, where smoking, poorly 
controlled hypertension and diabetes mellitus can cause high levels of circulating 
cholesterol and triglycerides, leading to lipid deposition in arterial vessel walls which 
causes arteries to become stenotic (19). Atherosclerosis causes poor perfusion, impairs 
skin oxygenation, and causes breakdown of the tissue. The wounds typically develop at 
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bony prominences or distal points and have dry necrotic wound beds, demarcated 
borders, and lack granulation tissue (11). 
Pressure ulcers affect up to 26% of patients in Canada (20) and are common in patients 
with impaired mobility or sensory perception, malnutrition, and fecal incontinence (11, 
12). They can start to develop in patients after just 2 hours of compression of soft tissues, 
and commonly occur when there is contact between a surface and bony prominence (19). 
Several factors can lead to the development of a pressure ulcer including sustained shear 
forces or forces perpendicular to the point of contact, friction that can lead to blisters or 
erosions, loss of elastin in aged skin that decreases resistance to pressure, and prolonged 
exposure to moisture (sweat, urine, fecal) that can result in breakdown of the skin (19). 
These factors result in localized tissue necrosis that leads to tissue injury (11). 
Currently in Canada, 3.5 million individuals live with diabetes (21) and up to 25% of 
these patients will be affected by a DFU in their lifetime (22). Neuropathy, vascular 
disease, and previous foot ulceration are major risk factors for the development of a 
diabetic ulcer (19, 23). Neuropathy can impair a patient’s joint mobility and cause an 
imbalance of pressure distribution on the foot, which can lead to the formation of calluses 
(19, 23). Additionally, the loss of sensation in the foot can result in repetitive injury that 
these patients are unable to detect (19, 23). Ischemia resulting from vascular disease 
impairs oxygenation of the feet leads to dry skin and results in breakdown of the tissue 
(11). DFUs are commonly located on the plantar surfaces of the feet where they are 
exposed to repetitive injury, with foot deformities and reduced joint mobility causing 
callus formation at abnormal pressure points (11). DFUs are a highly problematic 
outcome of diabetes, as they are the most common cause of non-traumatic lower limb 
amputations, with 15-20% of DFU patients requiring amputation (10). Furthermore, these 
amputations are associated with a high incidence of mortality (24). In Canada, the 
Canadian Diabetes Association reported that 30% of patients with diabetes will die within 
one year of amputation and 69% of patients with amputations will not survive past 5 
years (13). In addition to their comorbidities, DFUs burden the Canadian healthcare 
system, costing $150 million annually (13).  
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1.1.4 Current Treatments for Chronic Wounds 
Current management of chronic wounds is based on TIME guidelines which were first 
described by Schultz et al. (25). The TIME acronym refers to Tissue, Infection, Moisture 
Balance, and Wound Edge Management (26). In treating chronic wounds, the first step is 
to remove any necrotic tissue, which can impair healing. This non-viable tissue is 
removed through debridement that can be conducted using surgery, enzymatic digestion, 
or using biologic or mechanical methods (27). Bacterial infection of a wound can both 
delay healing and lead to systemic infections. To address this problem, wounds can be 
cleaned with water or saline and dilute acetic acid when they are prone to infection.  
Topical antimicrobial agents, including silver, gel beads for slow-release of cadexomer 
iodine, and manuka honey are also recommended for treatment of superficial wound 
infection (27). Moisture retentive dressings can be used to maintain sufficient moisture 
within the wound while controlling exudate. There are several types of dressings 
available although their applicability depends on the nature of the wound including level 
of exudate, depth and area of the injury, healing stage, and skin type (26, 27). Many 
biologic dressings are also available and are applied with the intent of creating a 
microenvironment supportive of healing. However, the efficacy of dressings is often 
specific to the type of chronic wound or underlying disease and there is often limited 
clinical support for their use (27).  
In addition to wound management, many adjunctive therapies exist for the treatment of 
chronic wounds including use of topical agents, bioengineered dressings, hyperbaric 
oxygen therapy, and negative pressure wound therapy. Currently, most topical agents 
available for chronic wound treatment target infection or have anesthetic properties (27). 
Regranex
TM
 is a topical formulation of PDGF and is currently the only growth factor 
approved by the Food and Drug Administration for the treatment of DFUs (10). Although 
clinical trials have shown an increase in wound closure with use of Regranex
TM
 relative 
to placebo controls (27), other studies in animal models have shown it to be less effective 
for full thickness wounds relative to other drug targets (28). Use of three or more tubes of 
gel is also associated with an increased risk of cancer-related mortality (10). 
PROMOGRAN® Matrix is another topical dressing agent used to inhibit protease 
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activity and is approved for use in chronic wounds (27). It has been shown to improve 
microcirculation in venous ulcers (29); however, a randomized controlled trial failed to 
demonstrate that PROMOGRAN® Matrix can significantly accelerate healing relative to 
controls (30). 
There are a growing number of bioengineered substitutes being developed for use in 
chronic wounds (27, 31, 32). The Integra Bilayer Wound Matrix is an acellular matrix 
consisting of a dermal layer of type I bovine collagen and shark chondroitin-6-sulfate and 
an epidermal layer of silicone (31). Case reports have described Integra Bilayer Wound 
Matrix as promoting healing in DFUs when used in combination with other treatment 
methods (33). A retrospective study reported an 81% healing rate of lower extremity 
wounds although only 16 patients were included in the study and not all wounds were 
considered chronic (34). Another acellular dressing is the OASIS® Wound Matrix which 
is made from porcine intestinal submucosa (27). A multicenter trial of patients with 
venous ulcers reported that a higher number of patients achieved complete wound closure 
when OASIS® was used relative to compression bandaging alone, although adverse 
events, including skin injury and infection, were also reported in two patients (31).  Skin 
substitutes containing cells include Dermagraft® and Apligraf®. Dermagraft® is a 
polyglactin scaffold implicated for treatment of DFUs. It contains human, neonatal-
derived fibroblasts and several growth factors, including TGF-β1, TGF-β3, TGF-α, 
heparin binding epidermal growth factor, PDGF-A, insulin-like growth factor, 
keratinocyte growth factor (KGF), and VEGF (10). Apligraf® is a matrix intended for 
use in diabetic and venous ulcers. It contains a stratum corneum of differentiated 
keratinocytes a dermal layer consisting of type I bovine collagen fibrils (10, 27). There is 
a stronger body of evidence supporting use of these products for treating chronic wounds, 
as numerous studies report their efficacy, showing improvements in healing relative to 
controls (27, 31). However, adverse events have been reported in some studies and multi-
center center studies for treatment of foot ulcers are still lacking (31, 35).    
For treatment of DFUs, hyperbaric oxygen therapy (HBOT) and negative pressure wound 
therapy can also be conducted in conjunction with other treatments. HBOT entails the 
delivery of 100% oxygen to the wound, usually for 90 minutes at 1.5-3.0 atmospheres. It 
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is typically conducted in daily sessions and is intended to increase oxygen saturation of 
the blood (36). Although there is some evidence to support its efficacy in healing DFUs 
in patients with concomitant ischemia (36), Health Quality Ontario reported that there 
was insufficient evidence for its use as adjunct to standard therapy for patients with non-
healing DFUs due to inconsistent results in randomized controlled trials (37). Negative 
pressure wound therapy can also be used for DFU treatment and entails the delivery of 
sub atmospheric pressures to the wound bed using a vacuum pump in order to promote 
cell proliferation in the wound bed (38). Although it is effective for post-surgical 
treatment of acute wounds, its efficacy has not yet been shown for chronic, non-healing 
wounds (38, 39). 
1.2 Pathophysiology of Chronic Wounds 
As previously discussed, chronic wounds do not follow the regular wound healing 
process, resulting in failure to achieve closure (40). Rather, these wounds have decreased 
levels of growth factors essential for the normal wound healing response including TGF-
β and VEGF, preventing essential processes such as re-epithelialization and angiogenesis. 
Additionally, chronic wounds have increased levels of expression of inflammatory 
cytokines, such as IL-1, IL-6, and TNF-α, which enhance the immune response and 
increase local inflammation (41). As a result, there is a continuous, self-perpetuating 
cycle of inflammation, preventing progression into the proliferative phase of healing and 
leaving the wound in a non-healing state regardless of wound management and 
intervention (12, 40). Several underlying factors lead to the continuous state of 
inflammation, including impaired processes such as re-epithelialization and granulation 
tissue formation, imbalances in proteolytic activity, bacterial colonization resulting in the 
development of biofilms, the accumulation of advanced glycation end products (AGEs, in 
diabetic patients), and the accumulation of oxidative stress in the wounds (12, 41). The 
independent role each of these factors plays in the perpetuating inflammation is discussed 
in depth below. 
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1.2.1 Impaired Re-epithelialization and Granulation Tissue 
Formation 
In chronic wounds, keratinocytes lack the ability to migrate, properly differentiate, and 
proliferate (41). Keratinocyte migration is impeded due to decreased levels of expression 
of EGF, FGF and TGF-α and their proliferation is reduced due to lower levels of KGF (9, 
42). Nuclear localization of β-catenin and overexpression of c-Myc also impede epithelial 
cell migration and supress their terminal differentiation (43). Together, these factors 
impede re-epithelialization as they prevent keratinocytes at the edge of the wound from 
migrating to form an epithelial barrier (41, 44).   
Chronic wounds also show a significant deficiency in granulation tissue formation. This 
is thought to be due to the overproduction of anti-angiogenic cytokines along with 
reduced production of pro-angiogenic cytokines and the sequestering of growth factors 
(45). Fibroblasts exhibit a phenotypic change in addition to decreased migration and 
proliferation (41). Their migration and secretion of collagenase is hindered, due to 
decreased levels of FGF-2 (9). Neovascularization is impaired due to decreased levels of 
VEGF and FGF-2 (9). Upon treatment with VEGF and FGF-2, diabetic mice have 
displayed significantly improved angiogenesis and accelerated wound healing (42). 
Levels of VEGF are decreased due to reduced amounts of TGF-β1 in the wounds, which 
acts to upregulate VEGF expression (9). Chronic wounds are also characterized by lower 
levels of PDGF, further impeding angiogenesis (42). Finally, lowered levels of TGF-β1 
decrease levels of fibronectin, collagen, and protease inhibitors, hindering new ECM 
formation (9).  
1.2.2 Imbalance of Proteolytic Activity 
A balance of activity between proteases and their inhibitors is required for the normal 
wound healing process to occur, as they play a functional role in the maintaining the 
integrity of the ECM and controlling its degradation to facilitate migration of cells into 
the wound (42, 46). In chronic wounds, this delicately controlled balance in protease and 
inhibitor levels is offset, with increased levels of MMPs and decreased levels of tissue 
inhibitor of metalloproteinases (TIMPs) being well documented in chronic wounds in 
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both animal models and studies investigating human chronic wound exudate (42, 47). 
These changes have been attributed to a lack of TGF-β1 in chronic wounds, which lowers 
TIMP levels by inhibiting their secretion by fibroblasts (42). Chronic wounds also exhibit 
a sustained increase in pro-inflammatory cytokines including IL-1β and TNF-α, which 
increase production of MMPs, including MMP-1, MMP-2, MMP-3, MMP-9, and MMP-
13 while reducing synthesis of TIMPs (9, 46). Moreover, the elevation of certain MMPs 
can activate other MMPs, triggering further increases in MMP levels (42). Increased 
MMP activity degrades ECM, inhibits cell migration, and reduces fibroblast proliferation 
and collagen deposition (12). MMPs have also been shown to degrade growth factors and 
their target cell receptors, including EGF/epidermal growth factor receptor (EGFR) and 
PDGF/platelet derived growth factor receptor further impairing the wound healing 
cascade (9, 46). This enhanced proteolytic activity, taken together with insufficient 
angiogenesis in chronic wounds, contributes to the inability to form proper granulation 
tissue (9). 
1.2.3 Biofilm Formation 
Bacterial colonization of chronic wounds is also known to play a contributing role in 
delayed healing, although the direct causal relationship in etiology is yet to be established 
(48). Upon formation of the wound, the resulting loss in barrier function leaves the 
wound susceptible to infection (23). Bacteria commonly found in wounds include 
Staphylococcus aureus, Pseudomonas aeruginosa and β-haemolytic streptococci and 
counts over 10
5
 bacteria per gram of wound tissue are considered detrimental to healing 
(12). Bacteria secrete a polymeric matrix adherent to the wound, forming a biofilm that is 
an environment optimal for their survival, as this matrix is resistant to both the innate 
immune mechanisms and antimicrobial agents (48, 49). Biofilms contribute to 
inflammation due to their effect on neutrophils and macrophages. Specifically, biofilms 
inhibit neutrophil chemotaxis and degranulation as well as preventing them from 
ingesting bacteria, resulting in increased secretion of pro-inflammatory cytokines. They 
also prevent the phagocytosis of neutrophils by macrophages, causing further 
dysregulation of inflammation (48). In animal models, biofilms have also been shown to 
delay re-epithelialization (50). 
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1.2.4 Advanced Glycation End Products 
AGEs are compounds formed through the Maillard reaction, which is a reaction that 
occurs between the amino groups of proteins and carbonyl groups of reducing sugars 
(51). AGEs are continuously produced in the body, but accumulate with the presence of 
hyperglycemia or oxidative stress (52). Higher levels of AGEs in skin have been 
associated with increased patient age, diabetes, as well as the presence of an ulcer in 
diabetic patients and there is a large body of evidence implicating their role in the 
pathogenesis of impaired diabetic wound healing (52, 53). AGEs can crosslink type I 
collagen which results in its decreased solubility and increased rigidity (52). They can 
also form on both laminin and type IV collagen, impairing both matrix-matrix 
interactions and cell-matrix interactions (54). Soluble plasma proteins, including albumin, 
fibrinogen, immunoglobulin, and low-density lipoprotein can also become glycated, 
altering their structure and function (51, 54). Glycated albumin plays a role in platelet 
activation and aggregation and glycated immunoglobulin is associated with inflammation 
(51).   
AGEs can also affect the function of wound healing cell types. In vitro studies have 
associated AGEs with impaired keratinocyte migration and proliferation (55). They have 
also been implicated in promoting apoptosis, inhibiting proliferation, and reducing 
secretion of ECM proteins by fibroblasts, including proteoglycans and hyaluronic acid 
(52). AGEs can also interact with AGE receptors on macrophages and endothelial cells, 
which causes oxidative stress and activates nuclear factor kappa-light-chain-enhancer of 
activated B cells (nf–κB). NF- κB increases production of pro-inflammatory cytokines 
including IL-1α, IL-6, and TNF-α (51). AGE binding to AGE receptors also increases 
production of vascular cell adhesion protein 1 and intracellular adhesion molecule 1 
(ICAM-1), which contribute to inflammation. The production of TNF-α results in 
increased production of reactive oxygen species (51). Sustained inflammation and 
oxidative stress further exacerbate AGE formation by increasing expression of AGE 
receptors through a positive feedback loop (52). 
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1.2.5 Oxidative Stress 
Wound fluid in patients with non-healing chronic wounds has shown significantly higher 
levels of oxidative stress relative to wound fluid in patients with healing wounds (17). 
Oxidative stress occurs when there is excessive generation of reactive oxygen species 
(ROS) relative to the antioxidant capacity (44). It can cause serious cellular damage by 
impairing mitochondrial function (56). Elevated levels of ROS are also associated with 
supporting migration of inflammatory cells into the wound, upregulating ICAM-1, which 
damages endothelial cells and facilitates recruitment of leukocytes, and impairing 
keratinocyte migration in vitro (47).  
Skin has a number of antioxidants including glutathione, ascorbic acid, and vitamin E, 
which are involved in infection control as well as reducing oxidative stress that is 
generated from inflammation in acute wounds (47). Chronic wound patients have been 
shown to have decreased levels of vitamins A and E. Lower limb ulcers have also been 
found to have decreased levels of selenium, a cofactor to glutathione peroxidase, as well 
as lower glutathione peroxidase activity (47). Lower levels of antioxidants combined with 
decreased antioxidant enzyme activity can debilitate antioxidant defense against 
oxidative stress (47). In patients with venous leg ulcers, iron overload also plays a 
contributing role to oxidative stress. Patients with venous leg ulcers have been shown to 
have higher levels of iron with concomitant elevation of MMP-9, suggesting that elevated 
iron deposits are released through activation of MMPs. Iron overload causes oxidative 
stress through the production of ROS including superoxide, nitric oxide, hydrogen 
peroxide, and peroxynitrite (17). 
Hyperglycemia resulting from diabetes can result in the over activation of several 
pathways. One such pathway is the hexosamine pathway, which inhibits the activity of 
glucose-6-phosphate dehydrogenase and limits the formation of nicotinamide adenine 
dinucleotide phosphate-oxidase (NADPH). Increased proteinase kinase C activity can 
also activate NADPH, depleting it (44). NADPH oxidase is required for the formation of 
reduced glutathione and nitric oxide, which act to neutralize reactive oxygen species; 
hence its depletion contributes to oxidative stress (44, 57). The polyol pathway, 
responsible for converting glucose to fructose, can also become over activated, resulting 
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in further depletion of NADPH oxidase. Over production of fructose through this 
pathway also contributes to the formation of AGEs, which accumulate with 
hyperglycemia as previously discussed (57). AGE binding to activated AGE receptors 
leads to the production of cytosolic ROS and the activation of NADPH oxidase, further 
sources of oxidative stress and cellular dysfunction (51, 58). Finally, the combination of 
hyperglycemia and presence of free radicals can activate the PARP pathway, further 
exacerbating oxidative stress (57).  
In summary, several factors act in combination to perpetuate the inflammatory response 
in chronic wounds, which plays an integral role in preventing a wound’s progression 
through the normal wound healing cascade (40). The consequences of remaining in this 
non-healing inflammatory state are severe, as wounds do not achieve closure, leaving the 
patient with a high risk of amputation (10), and consequently, at a high risk for mortality 
following amputation (24). Therefore, due to poor patient outcomes and limited treatment 
options, it is imperative that new treatment options be pursued. In light of the current 
knowledge on chronic wound pathology discussed above, new approaches for the 
treatment of chronic wounds should focus on modulating the inflammatory response, 
such that the proliferative phase of inflammation can be activated and therefore, the 
normal wound healing response achieved.     
1.3 Galectin-3 as a Therapeutic for Chronic Wounds 
Matricellular proteins are non-structural components of the extracellular matrix that 
become upregulated during wound healing and pathological processes. During the wound 
healing process, they act spatially and temporally to control specific cell behaviours 
(Figure 1.1) (59). Galectin-3 is a matricellular protein implicated in several inflammatory 
and immunomodulatory processes (60), making it an ideal candidate for treatment of 
chronic wounds. It has shown the ability to influence monocyte and macrophage 
migration (61), increase clearance of neutrophils (62), and regulate alternative 
macrophage polarization (63), all processes that can contribute to modulating the 
inflammatory response. Therefore, it is hypothesized that the use of galectin-3 will be 
effective in promoting healing in chronic wounds by stimulating the proliferative phase 
of healing.  
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Figure 1.1 – Upregulation of matricellular proteins during the wound healing 
response: Matricellular proteins upregulated during the wound healing response include 
galectin-3, osteopontin, thrombospondin 1 (TSP-1), tenascin-c (TN-C), thrombospondin 
2 (TSP-2), periostin, cysteine-rich angiogenic inducer 61 (CCN1), and connective tissue 
growth factor (CCN2). Galectin-3 expression peaks at day 1 following wounding in mice 
and persists throughout the inflammatory process (64). Reprinted with permission from 
Hamilton D, Walker J, Kim S, Michelsons S, Creber K, Elliott C, et al. Cell-matrix 
interactions governing skin repair: matricellular proteins as diverse modulators of cell 
function. Research and Reports in Biochemistry. 2015:73 (64). Copyright © 2015, Dove 
Press Ltd. 
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1.3.1 Protein Structure 
Galectin-3 is a protein consisting of 250 amino acids, separated into two distinct domains 
(Figure 1.2) (65). The carbohydrate recognition domain (CRD) of this protein accounts 
for approximately 130 amino acids and is globular in structure (66). The CRD domain 
contains S-lectin motifs that provide the protein with the ability to bind β-galactosides, a 
property shared by all proteins in the Galectin family (67, 68), as well as a nuclear export 
signal (69). 
In addition to its CRD, Galectin-3 contains an amino terminal domain, which spans 
approximately 120 amino acids and contains a highly conserved tandem repeat rich in 
proline, glycine and tyrosine (66, 70). The N-terminus contains a 12 amino acid leader 
sequence that is required for Galectin-3 secretion (66). Within this leader sequence 
serine
6
 can be phosphorylated, a process which significantly reduces binding to its 
ligands (laminin and mucin) and may act as an on/off switch for its ability to bind to 
sugars (71). The N-terminal domain also enables the formation of oligomers and is 
required for full biological function of the protein, including its role in modulating cell 
adhesion and inducing intracellular signalling (70, 72). Galectin-3 has been detected 
within cells, localized in the nucleus and cytoplasm, and has also been described outside 
of the cell, despite its lack of a known transmembrane domain and sequence (66, 73). It 
has been found to interact with a variety of wound healing cell types including, 
keratinocytes, fibroblasts, monocytes and macrophages (61, 74, 75). 
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Figure 1.2 – Domains and structures of recombinant human galectin-3: Human 
recombinant galectin-3 is a protein consisting of 250 amino acids. It features a 120 amino 
acid N-terminal region that contains a leader sequence and a tandem repeat region rich in 
proline, glycine and arginine. It also comprises of a CRD containing a β-galactoside 
binding region and a sequence required for nuclear export. 
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1.3.2 Role in Inflammation 
Galectin-3 has been demonstrated to influence a variety of processes associated with 
inflammation through its interaction with various cell types including neutrophils, 
monocytes, and macrophages. In the initial stages of inflammation, neutrophils are 
recruited to the wound to eliminate foreign particles and bacteria. In vitro studies have 
shown that recombinant human galectin-3 can activate neutrophils in a dose-dependent 
manner, through a process involving its CRD (76). A study investigating NADPH 
oxidase activity revealed that galectin-3 activated exudate neutrophils, with increased 
activity corresponding to increased surface-bound protein, while activity was unaltered in 
peripheral neutrophils (77). In addition to neutrophil activation, galectin-3 has shown to 
facilitate neutrophil adhesion to laminin in vitro and has been implicated in the 
recruitment of neutrophils in a murine model of cutaneous infection (78, 79). 
The inflammatory phase of healing also involves the recruitment of monocytes to the 
wound, which differentiate into macrophages of varying phenotypes that play distinct 
roles in inflammatory processes (80). Galectin-3 induces monocyte migration in vitro, 
stimulating chemotaxis at high concentrations and chemokinesis at lower concentrations. 
A migratory effect from galectin-3 is also observed in macrophages (61). Migration in 
both monocytes and macrophages is increased in the presence of fibronectin, suggesting 
that galectin-3 may mediate linkage of these cells to fibronectin (81). One of 
macrophage’s roles in inflammation is to rid the wound of neutrophils, ingesting them 
and inducing their apoptosis (80). In vitro studies suggest that galectin-3 can influence 
this process as addition of exogenous galectin-3 increases apoptotic neutrophil uptake in 
macrophages. It has also been postulated that galectin-3 acts as an opsonin, linking the 
phagocytic macrophages to the neutrophils (62). A study conducted by MacKinnon et al. 
investigated the effect of galectin-3 on macrophage activation in bone marrow derived 
macrophages in vitro and in resident lung and recruited peritoneal macrophages in vivo. 
Interestingly in all macrophages derived from galectin-3 deficient mice, IL-4/IL-13-
induced M2 macrophage polarization was inhibited, suggesting that galectin-3 is 
involved in the regulation of alternative macrophage activation (63). A summary of 
macrophage activation and polarization is shown in Figure 1.3. 
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Figure 1.3 – Macrophage activation and polarization: Monocytes can undergo 
classical activation in the presence of interferon gamma (IFN-γ) and lipopolysaccharides 
(LPS) or TNF-α into M1-polarized macrophages, which are associated with 
inflammation. M1 macrophages produce inducible nitric oxide synthase (iNOS) as well 
as pro-inflammatory cytokines. In mice, markers of M1 macrophages include iNOS, 
chemokine ligand 9 (CXCL9), CXCL 10, and CXCL11. Monocytes can undergo 
alternative activation through stimulation with IL-4 or IL-13 into M2-polarized 
macrophages. M2 are associated with tissue remodeling and secrete arginase I and anti-
inflammatory cytokines. M2 markers in mice include arginase I, Mrc I, Fizz I, Ym1, and 
Ym 2 (8, 80, 82). 
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1.3.3 Role in Angiogenesis 
Galectin-3 has been shown to induce angiogenesis both in vitro and in vivo. In vitro, the 
protein stimulated capillary tube formation of human umbilical cord endothelial cells 
grown on a matrigel, while in vivo, a galectin-3-loaded matrigel was able to induce 
angiogenesis in nude mice. Both of these processes relied on its CRD (83). Markowska et 
al. later proposed that galectin-3 modulated VEGF and FGF-2-mediated angiogenesis by 
activating focal adhesion kinase-mediated signalling pathways that modulate endothelial 
cell migration during this process (84). The protein has also been linked to angiogenesis 
and the migration of endothelial cells through integrin-linked kinase signalling (85). 
Galectin-3 was also shown to bind to vascular endothelial growth factor receptor 2 
(VEGFR2), promoting its phosphorylation and preventing its internalization, leading to 
an increased angiogenic response of human umbilical cord endothelial cells to VEGFA in 
vitro (86).  
In combination with galectin-1, galectin-3 can activate and prevent the internalization of 
VEGFR1, another process that enhances angiogenesis (85). Despite these findings, a 
recent study in mice showed that during wound repair in skin, galectin-3 deficient mice 
have no difference in vascular density or expression of angiogenic markers relative to 
wild-type mice (87). These conflicting findings indicate that the role of galectin-3 in 
angiogenesis likely tissue and context-dependant (64).  
1.3.4 Role in Re-epithelialization 
The first association of galectin-3 with re-epithelialization came from Kasper and Hughes 
who noted the surface expression of galectin-3 in Type I and II alveolar epithelial cells in 
a model of irradiation-induced lung inflammation and repair (88). In a model of corneal 
wound healing, galectin-3 deficient mice were found to exhibit reduced re-
epithelialization rates relative to wild-type counterparts. Interestingly, galectin-3 did not 
alter proliferation rates of epithelial cells and elevated levels of galectin-3 were detected 
in the migrating epithelial front following injury, suggesting the protein promotes 
epithelial cell migration (89). This was supported by later studies showing that galectin-3 
promotes cell scattering, lamellipodia formation, and motility in human corneal epithelial 
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cells (90). Furthermore, studies in mouse corneas showed that galectin-3 knockout mice 
exhibit impaired re-epithelialization (89). The effect of the addition of exogenous 
galectin-3 has also been investigated in models of murine corneal healing, where the 
addition of exogenous galectin-3 increased re-epithelialization in wild type (WT) mice, 
but not galectin-3 deficient mice (89). The increase in re-epithelialization in WT mice 
was attributed to the modulation of galectin-7 by exogenous galectin-3, as galectin-7 was 
found to accelerate re-epithelialization in galectin-3 knockout mice and because mouse 
embryonic fibroblasts from galectin-3 knockout mice showed reduced levels of galectin-7 
(89). Studies of epithelial wounds in monkey corneal explants also demonstrated 
enhanced re-epithelization when recombinant human galectin-3 was added exogenously 
to the media (91). 
Consistent with studies in the cornea, studies in skin have revealed that keratinocytes 
from galectin-3 knockout mice exhibit a migratory defect (75), and that re-
epithelialization is delayed in galectin-3 deficient mice (75, 87). However, in skin this 
defect was attributed to deficient EGFR endocytosis and recycling, which is controlled by 
cytosolic galectin-3 binding to ALG-2 interacting protein X (ALIX) (75). Additionally, 
there were no differences between levels of galectin-7 in wound tissue from WT and 
knockout mice at day 7 post injury, during which re-epithelialization was impaired (87). 
Taken together, galectin-3 has been implicated in several processes associated with 
wound healing, including modulating inflammation and contributing to re-
epithelialization. As a result, delivery of this protein during the wound healing process, 
either topically or via a scaffold, is a potential new therapeutic to enhance repair.   
1.4 Protein Delivery Strategy 
1.4.1 Scaffolds for Protein Delivery 
Although several growth factors and peptides have demonstrated therapeutic potential for 
chronic wound healing, the effectiveness of applying such treatments topically is limited, 
due to the peptidase-rich wound microenvironment, which impairs the bioactivity of 
peptides, and the short half-life of both peptides and growth factors (92, 93). The use of 
scaffolds for delivery of therapeutic agents aims to overcome this challenge. A scaffold is 
23 
 
a three-dimensional polymeric structure used to treat a defect by acting as an artificial 
ECM to guide regeneration (94). Their use in the delivery of bioactive molecules offers 
several advantages, including protecting peptides from rapid biodegradation, providing a 
large surface area to enable the effective delivery of bioactive molecules, and controlling 
the release of bioactive molecules so that signals are provided continuously throughout 
healing (93, 95). Using this method of delivery, the therapeutic agent is able to recruit 
progenitor cells to the defect and guide cell behavior towards a pro-regenerative response 
(95). Meanwhile, the scaffold nanotopography is also important in this process, providing 
a site for cell adhesion and supporting cell proliferation and migration (96-99). Through 
selection of appropriate therapeutic agents and appropriate scaffold design it is intended 
that the application of a scaffold to a chronic wound microenvironment will be able to 
achieve healing by stimulating a pro-regenerative response. 
1.4.2 Scaffold Design for Tissue Regeneration 
The overall aim in scaffold fabrication is to design an artificial matrix that closely mimics 
the ECM of the immature granulation tissue (94). Within skin, the dermis consists largely 
of collagen and contains a meshwork of fibers within the range of 30-130 nm (100). This 
ECM is responsible for providing mechanical support as well as modulating cell 
proliferation, migration, differentiation and apoptosis (100). Therefore it is ideal that a 
scaffold contains fibers with diameters within this range. A high porosity is also needed 
to support cell ingrowth and to facilitate the diffusion of waste and nutrients (101). 
Several electrospun scaffolds have been able to obtain porosity values between 60-90%, 
although 90% porosity has been suggested to be an ideal target (96, 101-103). Scaffolds 
having pore sizes of approximately 100 μm and porosity in the 90% range have shown 
the ability to support the infiltration of cells beyond the surface of the scaffold (104). 
These considerations ensure a high surface area to volume ratio which can accommodate 
high cell densities (100). Through selection and optimization of scaffold materials, it 
should also be ensured that the rate of scaffold degradation coincides with the rate of 
tissue regeneration. Finally, the material itself, along with degradation products, must be 
biocompatible to ensure it will not elicit an immune response within the host tissue (100). 
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1.4.3 Scaffold Materials 
Scaffolds can be fabricated from a wide range of materials that include natural polymers, 
synthetic polymers, and polymer composites. Naturally derived polymers commonly used 
in wound healing include collagen, gelatin, chitosan, and silk fibroin (105). Currently, the 
majority of artificially made skin substitutes approved for clinical use are collagen-based 
scaffolds. These scaffolds typically consist of Type I collagen as it is the predominant 
component of the dermal ECM (105). The use of collagen in scaffolds is advantageous as 
it can regulate the adhesion, migration, proliferation, differentiation and survival of cells 
(106). One limitation to collagen scaffold fabrication is that pure collagen is relatively 
expensive (107). The processing of collagen during scaffold fabrication can also alter its 
biological and structural properties (108). For example, Zeugolis et al. found that the 
electrospinning of collagen resulted in its denaturation (109). Alteration of collagen 
structure can also be caused by many sterilization methods (106). Gelatin is a denatured 
form of collagen, which can be obtained through both alkaline or acid processing of 
collagen (106). Use of gelatin for scaffold fabrication is desirable, as it maintains the 
composition and properties of collagen, while also being commercially available at a low 
cost (108, 110). Conversion of collagen to gelatin increases exposure of RGD sequences, 
which may increase cell signaling (111). The use of electrospun gelatin scaffolds has 
been shown to facilitate the adhesion, migration and proliferation of wound healing cell 
types, and to increase wound closure in a full thickness wound model in rats (96-99). 
Overall, natural polymers are strong candidates for wound healing applications as they 
are biodegradable and biocompatible, supporting cell viability; however, they require 
crosslinking to control their rate of degradation and mechanical properties (106, 108). 
Synthetic polymers include poly-lactic acid (PLA), polycaprolactone (PCL) and poly-
glycolic acid (PGLA). There are several advantages for the use of synthetic polymers in 
scaffold fabrication. They are well defined in structure, therefore there is no variation 
between batches and fine tuning of both their mechanical properties and degradation 
kinetics can be conducted to suit their application. They can also be supplied in large 
quantities and are typically less expensive than natural polymers (112). However, cell 
viability decreases when synthetic polymers are used as these materials have hydrophobic 
25 
 
surfaces, lack the appropriate cell recognition sites and have lower rates of cell adhesion 
and proliferation (105, 107, 112, 113). To overcome these challenges, researchers are 
attempting to improve the adhesive properties of these scaffolds by incorporating proteins 
and amino acids including arginine-glycine-asparagine (RGD) sequences, cysteine, 
lysine, laminin, and collagen-like proteins (114). 
The use of polymer composites aims to overcome the limitations of both natural and 
synthetic polymers to ultimately create scaffolds with the appropriate biocompatibility as 
well as physical, mechanical, and chemical properties (107). In this method, a natural 
polymer, such as collagen, gelatin, or chitosan can be blended with a synthetic polymer 
such as PCL. This is done at an optimized concentration to improve the mechanical 
stability using the synthetic component, while also improving the biocompatibility by 
increasing hydrophilicity and by providing integrin binding sites through the natural 
component (115, 116). This method also eliminates the need for pre-treatment of the 
scaffolds to improve functionality (116). Blends of PCL/collagen were found to have 
more stability relative to collagen-only scaffolds, while also having higher cell 
proliferation than PCL alone (117). Blends of poly(L-lactic acid)-co-poly(ε-caprolactone) 
(PLACL)/gelatin have also shown significantly higher proliferation of cells relative to 
PLACL blends after 6 days in culture (115). 
1.4.4 Scaffold Fabrication Methods 
Several techniques are currently used for the fabrication of scaffolds in skin regeneration. 
Freeze-drying, or lyophilization, is a process in which water is used to create porous 
hydrogels (105). The process involves freezing a solution at a temperature between -70°C 
and -80°C, followed by application of a partial vacuum to lower the pressure so that ice 
can be removed from the material through sublimation.  Unfrozen water is them removed 
by desorption (118). This method is advantageous due to its use of water rather than 
organic solvents during the fabrication process (118). The procedure can also be modified 
to control the pore size and scaffold morphology (105). Decreasing the freezing rate has 
been associated with increasing the resulting pore sizes in the fabrication of plant-derived 
collagen sponges (119). In the lyophilization of gelatin, increasing the concentration of 
gelatin can decrease the pore size, while increasing the freezing temperature creates 
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larger mean pore sizes. Pore arrangement in parallel sheets can also be achieved by 
conducting freezing at -196°C in liquid nitrogen (105). Although a simple technique, 
freeze-drying is expensive and typically requires longer processing times than other 
fabrication methods. Scaffold porosity is also often irregular and the surface is typically 
dense, hindering cell migration into the inner areas of the scaffold (120, 121). Surface 
skin, which is the collapsing of the material’s internal pores due to lack of structural 
integrity, can also occur during the freeze-drying process if the freezing temperature is 
too high (105). 
Gas foaming is a technique in which a foaming agent such as sodium bicarbonate is 
added to a hydrogel to create an inert gas, typically N2 or CO2. The pores are generated 
from subsequent removal of the gas phase from the polymer and surfactants are typically 
added to stabilize the foam that is created during the separation process (122). Using this 
technique, the pore size and morphology of the scaffold can be modified by adjusting the 
temperature and pressure during the procedure (105). Several other advantages include 
the ability of this method to achieve high scaffold porosities and that the technique can be 
conducted without the use of an organic solvent, enabling the incorporation of bioactive 
molecules without their degradation (105, 121). However, the use of surfactant in this 
method has the potential to negatively impact scaffold biocompatibility (122). 
Solvent casting/ particle leaching is another scaffold fabrication method in which a 
porogen, commonly sodium chloride, is added to a polymer solution that is placed into a 
mould. The porogen is subsequently leached or removed through application of the 
appropriate solvent (105). The pore sizes can be easily controlled by modifying the 
particle size of the porogen (105). The mechanical strength of the scaffolds, rate of 
biodegredation and porosity of the scaffolds can also be easily modified by adjusting the 
concentration of the porogen (120). One drawback of this process is that longer 
processing times are required due to the leaching step (121). The width of the scaffold is 
also limited as it is difficult to remove the salt particles from the center of the material. 
Thus, as the thickness increases, residual salt particles may remain within the material 
(105). Another limitation of the salt/leaching method is that the leaching process often 
requires the use of organic solvents which could negatively impact cell viability (105).  
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While the aforementioned methods have their merits, electrospinning was the method of 
choice due to the numerous advantages discussed below. In the electrospinning method, a 
polymer solution is passed through a needle using an applied force from a syringe pump. 
An electric potential is applied to the needle through which the polymer solution passes 
such that as each droplet accumulates at the tip of the needle, it experiences electrostatic 
repulsion between the surface charges of the droplet and Columbic force exerted by the 
applied electric field (100). As charge accumulates on the surface of the droplet, a Taylor 
cone is formed (100). Once the electrostatic charge exceeds the surface tension of the 
polymer solution, a polymer jet is expelled and travels towards a grounded mandrel 
(108). During this process, the solvent becomes evaporated, leaving dried fibers 
deposited on the mandrel (105). 
The use of electrospinning as a technique for creating scaffolds with nanotapographies 
offers several advantages. Firstly, the electrospinning apparatus requires a minimal 
amount of specialized equipment and is inexpensive relative to other technologies to set 
up and operate (107, 108). The simplicity of the technique also makes it ideal for scale-up 
and large-scale production (108). The technique is versatile, enabling it to be used for 
many types of polymer and solvent systems. In fact, over 100 types of natural and 
synthetic polymers have been electrospun with success (123). The properties of the 
resulting fiber mats can also be tuned for the desired application. For example, the size 
and shape of the scaffold can be varied through changing the collector substrate, and the 
thickness of the scaffolds can be adjusted by changing the volume of the polymer 
solution that is electrospun (100, 108). Parameters can also be modified to produce mats 
with fibers that are randomly dispersed or aligned in uniaxial arrays (100, 123). 
Furthermore, the resulting matrices are highly porous, having large surface area to 
volume ratios, making them ideal for cell attachment and the exchange of nutrients and 
waste (107, 123). Finally, the fibers can also be used for the encapsulation of ECM 
proteins, enzymes, and growth factors (123). 
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1.4.5 The Addition of Bioactive Compounds to Electrospun 
Scaffolds 
A simple approach for loading bioactive molecules into electrospun scaffolds is to use the 
blend electrospinning method. In this method, the bioactive molecules are simply mixed 
in the polymer solution prior to electrospinning. The resulting fibers have the bioactive 
molecules dispersed within them enabling a more controlled release relative to the 
physical adsorption of the molecules onto the scaffold surface. Using this method, there 
is typically an initial burst release in vivo followed by a sustained release caused by 
diffusion of the bioactive molecule and degradation of the polymer (95).   
Several groups have used blend electrospinning with success, creating scaffolds for the 
release of ECM proteins, peptides and growth factors while retaining bioactivity. Several 
growth factors important to the wound healing process, including VEGF, PDGF, FGF 
have been incorporated into scaffolds and have demonstrated support of the growth and 
proliferation of cell types including keratinocytes, fibroblasts and endothelial cells (124, 
125). Bertoncelj et al. demonstrated that platelet rich plasma, which is known to be 
abundant in different growth factor types, can be delivered using chitosan/polyethylene 
oxide scaffolds, stimulating proliferation of keratinocytes and fibroblasts in vitro (126). 
Polyvinyl alcohol scaffolds have also been developed for the delivery of antifungal 
peptide Cm-p1 (127). Our group has previously shown that type I collagen scaffolds 
loaded with the matricellular protein periostin are able to recover alpha-smooth muscle 
actin expression in wounds of periostin knockout mice (128). Another group developed 
silk fibroin/gelatin scaffolds loaded with astragaloside IV, a natural herb. When tested in 
vivo, the scaffolds were able to accelerate healing and prevented scar formation by 
stimulating wound closure in partial thickness burn wounds in rats (129). Neurotensin-
loaded collagen scaffolds have also been shown to reduce inflammation and improve 
wound closure in streptozotocin-induced diabetic mice (93). More complex blends of 
bioactive compounds have also been incorporated into scaffolds. Peh et al. incorporated 
vitamin C, fat soluble vitamin D3, hydrocortisone, insulin, triiodothyronine, and EGF 
into poly (lactic-co-glycolic acid)/collagen scaffolds without loss of bioactivity. The 
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resulting scaffolds were able to induce proliferation of keratinocytes and fibroblasts in 
vitro (130). 
1.5 Hypothesis and Objectives 
1.5.1 Rationale 
The electrospinning method can generate both collagen and gelatin fibers ranging from 
50-500 nm, providing a biocompatible matrix of fibers within range of the native tissue 
collagen fibrils (116, 131-134). The use of gelatin in electrospinning is preferable, as it is 
similar in structure to collagen, which accounts for 70-80% of the skin’s dry weight, 
while being considerably less expensive (135). Electrospun scaffolds have been 
successful in supporting cell behaviour such as adhesion, proliferation and scaffold 
infiltration as well as demonstrating enhanced wound closure kinetics in mouse 
excisional wound healing models (96-99). In addition to acting as a matrix for cell 
infiltration, scaffolds can also be used as delivery vehicles for growth factors and ECM 
proteins in order to stimulate certain cellular behaviours and responses (128, 130, 136, 
137). In this work, a nanofibrous gelatin scaffold will be fabricated for the purpose of 
delivering exogenous galectin-3. 
The addition of exogenous galectin-3 in a model of impaired wound healing has not yet 
been investigated in skin. Previous studies have shown that galectin-3 knock-out mice do 
not exhibit altered wound closure kinetics (87), although models of both corneal and skin 
wound healing reveal that galectin-3 deficient mice exhibit delayed re-epithelialization 
(75, 87, 89). Despite unaltered wound closure kinetics in galectin-3 knockout mice, 
studies in mouse and monkey corneas reveal that the addition of exogenous galectin-3 
enhances wound re-epithelialization in WT mice (89, 91). Whether galectin-3 has a 
similar effect in WT mice in skin is unknown. Moreover, whether it could represent a 
therapeutic for reversing impaired wound healing has not yet been tested. 
Macrophages play a critical role in regulating the inflammatory phase of wound healing. 
Classically activated macrophages, defined by their secretion of nitric oxide and pro-
inflammatory cytokines, such as TNF-α, IL-6 and IL-12, exhibit pro-inflammatory 
properties, while alternatively activated macrophages, defined by stimulation by IL-4 and 
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IL-13 have the ability to control inflammation (8). Galectin-3 has previously been shown 
to regulate alternative macrophage activation in vitro, with galectin-3 deficient cells 
showing reduced levels of arginase I (63), therefore it will be interesting to determine 
how delivery of exogenous galectin-3 via a gelatin scaffold will influence macrophage 
polarization relative to a gelatin scaffold. 
1.5.2 Hypothesis 
We hypothesize that local delivery of galectin-3 either topically or using a gelatin 
scaffold will accelerate skin wound closure in WT and db/db mice relative to empty 
wounds. We secondarily hypothesize that the delivery of galectin-3 either topically or 
using a gelatin scaffold will increase re-epithelialization and modulate inflammation by 
stimulating M2 macrophage polarization. 
1.5.3 Objectives 
The objectives for this thesis were the following: 
1. To develop a scaffold for the delivery of exogenous galectin-3 
2. To evaluate the biocompatibility of the gelatin/galectin-3 scaffolds in vitro using 
human dermal fibroblasts 
3. To evaluate the effect of the gelatin/galectin-3 scaffold on wound healing in 
murine models 
a. Assess the influence of the scaffold on wound closure kinetics 
b. Compare and contrast the efficacy of local delivery of topical galectin-3 
versus gelatin/galectin-3 electrospun scaffolds on re-epithelialization and 
macrophage polarization during skin healing. 
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Chapter 2  
2 The Influence of a Gelatin/Galectin-3 Scaffold on 
Normal and Impaired Models of Skin Healing 
2.1 Introduction 
Normal skin healing involves a series of four overlapping phases: hemostasis, 
inflammation, proliferation and remodeling (1). During healing, these processes occur in 
a spatiotemporal manner to remove bacteria and damaged cells, restore the epithelial 
barrier, as well as to synthesize and remodel the extracellular matrix at the site of injury, 
restoring tissue function (2). Chronic wounds result when wounds fail to complete this 
process and achieve healing, usually within twelve weeks of initial injury, resulting in 
impaired tissue function and anatomy (3). The most common types of chronic wounds are 
venous ulcers, arterial ulcers, pressure ulcers, and diabetic ulcers (3, 4). A variety of 
factors can lead to their development, including vascular insufficiency, diabetes, 
malnutrition, patient age, pressure, infection, and edema (5). These wounds become a 
significant burden to the patient, as they can be painful, impair limb function, and result 
in sepsis or the need for amputation (5). In addition, the burden to the Canadian 
healthcare system is large, with the average cost of chronic wound treatment being 
$10,376 (6). 
Conventional treatment strategies involve removal of necrotic tissue, cleaning of the 
wound, and use of antimicrobial agents to treat infection. Dressings can be applied to 
retain moisture and promote healing, although their efficacy depends on specific wound 
characteristics including the amount of exudate, depth and area of the wound, stage of 
healing, and skin type of the patient (7, 8). Many adjunctive therapies are also available 
for the treatment of chronic wounds including topical formulations, bioengineered skin 
substitutes, hyperbaric oxygen therapy, and negative pressure wound therapy (8-12). 
However, support for their use in this application is limited, as many treatments lack 
multi-center studies that apply to broader patient populations and to non-healing chronic 
wounds (11, 12). Therefore, new treatment strategies aimed at promoting healing in 
chronic wounds are needed. 
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When considering the development of new therapeutics for chronic skin wounds, it is 
extremely important to factor in the underlying pathophysiology. Chronic wounds are 
stalled in a deleterious pro- inflammatory state, with increased expression of 
inflammatory cytokines such as interleukin-1 (IL-1),  IL-6, and tissue necrosis factor 
alpha (TNF-α), coupled with decreased levels of pro-regenerative cytokines including 
transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF) 
(13). Several molecular processes are known to exacerbate the inflammatory processes 
and prevent progression into the proliferative phase of healing. The decreased levels of 
growth factors, including keratinocyte growth factor, fibroblast growth factor 2 (FGF-2), 
and VEGF, impede keratinocyte migration and granulation tissue formation (14, 15). 
Additionally, there is an imbalance of proteolytic activity that leads to excessive 
degradation of the extracellular matrix, inhibiting cell migration and proliferation (5, 15, 
16). In diabetic patients,  advanced glycation end products (AGEs) also accumulate due 
to hyperglycemia (17) and can cause oxidative stress through interaction with AGE 
receptors on macrophages and endothelial cells, triggering the release of pro-
inflammatory cytokines (18). Considering the pathophysiology of chronic wounds, 
therapeutic agents that can regulate inflammatory processes present an ideal treatment 
strategy.    
Galectin-3 is a protein implicated in the regulation of several processes required in 
wound healing, particularly inflammation. Galectin-3 consists of a 120-amino acid N-
terminal domain and a 130-amino acid carbohydrate recognition domain (CRD) 
providing the capability to bind β-galactosides (19-21). In vitro, it has been shown to 
increase migration of monocytes and macrophages (22). Additionally, galectin-3 has been 
shown to link phagocytic macrophages to neutrophils as well as increase their neutrophil 
uptake (23). This protein has also been associated with regulating alternative macrophage 
activation, a process important in resolving inflammation (24). Studies in galectin-3 
knockout mice have shown that re-epithelialization is impaired in both the cornea and in 
skin, suggesting an important role for galectin-3 in re-epithelialization (25-27). In skin, 
impaired re-epithelialization is attributed to deficient epidermal growth factor receptor 
(EGFR) endocytosis and recycling, a process controlled by cytosolic galectin-3 binding 
to ALG-2 interacting protein X (ALIX) (27). In the cornea, the addition of exogenous 
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galectin-3 led to increased re-epithelialization, credited to its upregulation of galectin-7 
which is decreased in mouse embryonic fibroblasts (25); however in skin, differences in 
expression of galectin-7 in wound tissue are not observed concomitantly with impaired 
re-epithelialization (26). The role of galectin-3 in promoting re-epithelialization and 
modulating inflammation suggest that delivery of this protein to chronic wounds would 
promote pro-regenerative processes. Therefore, investigation of this protein as a potential 
therapeutic agent is needed. 
Several groups have previously shown that growth factors, bioactive peptides, 
matricellular proteins, and combinations thereof can be incorporated into scaffolds, while 
exhibiting biological activity either in vitro or in vivo (28-31). Electrospinning is a 
versatile technique for scaffold fabrication that can be fine-tuned to produce highly 
porous fiber mats with large surface area to volume ratios (32, 33). Delivery of human 
recombinant galectin-3 via an electrospun scaffold in wound healing is of interest, as the 
scaffold would provide a large surface area, enabling effective delivery and distribution 
of the protein in the wound bed to ensure that signals are provided continuously 
throughout healing (20). In addition, the scaffold would act as an artificial extracellular 
matrix, guiding regeneration by providing a site for cell adhesion and supporting the 
proliferation and migration of cells into the wound bed (34-37). 
The aim of this study was to fabricate a gelatin scaffold for the delivery of recombinant 
human galectin-3 using the blend electrospinning method, to test its biocompatibility in 
vitro and to test its efficacy in dermal wound healing in vivo. The adhesion, proliferation 
and secretion of extracellular matrix proteins by human dermal fibroblasts on 
gelatin/galectin-3 scaffolds were assessed in comparison to gelatin scaffolds. The 
influence of the gelatin/galectin-3 scaffold in wound healing was then evaluated.  
Evaluation was based on its effect on wound closure kinetics, re-epithelialization and 
macrophage populations in vivo relative to treatment with topical galectin-3 and gelatin 
scaffolds. 
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2.2 Materials and Methods 
2.2.1 Electrospinning 
As shown in Figure 2.1, a polymer solution consisting of Type B Bovine gelatin (Sigma-
Aldrich, St. Louis, MO, USA) dissolved in 40% v/v acetic acid (Thermo Fisher 
Scientific, Waltham, MA, USA) was passed through a plastic 1cc syringe (Terumo, 
Shibuya, Tokyo, Japan) and 20 gauge blunt-tip stainless steel needle using a syringe 
pump (VWR International, Radnor, PA, USA). The needle was connected to a high 
voltage DC power supply (Gamma High Voltage Research, Ormond Beach, FL, USA) 
and a grounded stainless steel rotating mandrel. The mandrel speed was held constant at 
100 revolutions per minute (RPM). The gelatin concentration, flowrate and collector 
distance were varied as outlined in Table 1. 
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Table 1: A summary of parameter combinations used during electrospinning to 
compare the effects of the flowrate and collector distance on the resulting fiber 
diameter 
Concentration of Gelatin 
 (% Weight) 
Flowrate 
(mL/h) 
Collector Distance  
(cm) 
20 0.1 6 
20 0.1 10 
20 0.1 14 
20 0.3 6 
20 0.3 10 
20 0.3 14 
20 0.5 6 
20 0.5 10 
20 0.5 14 
25 0.5 10 
30 0.5 10 
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To fabricate each gelatin/galectin-3 scaffold, 5 μL of a 1 mg/mL solution of recombinant 
human galectin-3 (R&D Systems, Minneapolis, MN, USA) in phosphate buffered saline 
(PBS) was added to 0.75 mL of the polymer solution (gelatin and acetic acid) for a final 
concentration of 6.7 μg/mL. Low concentration gelatin/galectin-3 scaffolds were 
fabricated using a 0.5 mg/mL solution of galectin-3 in PBS, resulting in a final 
concentration of 3.3 μg/mL. In gelatin scaffolds, 5 μL of PBS was added to the 
electrospinning solution. Scaffolds were produced by electrospinning for 1.5 hours using 
a total volume of 0.75 mL of each solution. Scaffolds were then crosslinked in a glass 
desiccator (VWR International) containing drierite (W.A. Hammond Drierite Co. Ltd, 
Xenia, OH, USA) using the vapour from a 5 mL solution consisting of 1.5% v/v 
glutaraldehyde (GTA) (Sigma-Aldrich, St. Louis, MO, USA) in anhydrous ethyl alcohol 
(Commercial Alcohols, Brampton, ON), similar to the methods of Zha et al. (37).  The 
desiccator was held under vacuum for 20 minutes and scaffolds were left in the sealed 
desiccator for 48h to ensure sufficient crosslinking had taken place.  Following 
crosslinking, scaffolds were stored in separate sealed plastic containers with desiccant at 
2-8°C. 
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Figure 2.1 – Schematic representation of the electrospinning process: A syringe 
pump is used to feed the polymer solution through a 1cc syringe and 20 gauge needle at 
the desired flowrate (0.1-0.5 mL/h). The needle is connected to a power supply and 
grounded collector, creating an electric potential of 15 kV. Fibers are collected on a 
rotating mandrel collector positioned 6-10 cm away from the tip of the needle.   
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2.2.2 Assessment of Fiber Morphology 
Three separate scaffolds (N=3) were electrospun at each set of conditions listed in Table 
1. One circular sample (8 mm diameter) of as-spun fibers was collected per scaffold 
using a biopsy punch (Integra Miltex,York, PA, USA). Samples were mounted on 
aluminum stubs and sputter coated with osmium. Images were taken for each sample 
using a scanning electron microscope (LEO 1530; Carl Zeiss, Oberkochen, Germany) at 
2 kV and one of three magnifications: 1000X, 3000X, or 5000X. Using ImageJ software 
(National Institutes of Health, Bethesda, MD, USA), the diameter of 250 fibers (N=3), 
were measured from 5 separate images taken at the same magnification. 
2.2.3 Mercury Porosimetry 
Mercury porosimetry was used to assess the porosity of the refined gelatin scaffolds. For 
each test, two scaffolds were electrospun from the same polymer solution for 1.5 hours 
using the parameters outlined in Table 1. The scaffolds were subsequently crosslinked for 
48 hours in 1.5% GTA vapour as previously described. Both scaffolds, measuring 
approximately 4 x 10 cm were then removed from the aluminum foil, folded and placed 
together in a 5cc stem which was loaded into the AutoPore IV 9500 mercury porosimeter 
(Micrometrics Instrument Corp., Norcross, GA, U.S.A). The porosimeter generated a 
pore size distribution, calculated the scaffold porosity and calculated the average pore 
diameter (pore size) of the scaffolds.  
2.2.4 Mass Spectrometry 
Mass spectrometry was used to validate the presence of galectin-3 within the scaffold. 
Prior to conducting mass spectrometry, three gelatin/galectin-3 scaffolds (6.7 μg/mL) 
were blend electrospun and crosslinked as described in section 2.2.1. One piece of each 
scaffold measuring approximately 9 cm
2
 was cut from each scaffold for mass 
spectrometry. Each sample was then processed and mass spectrometry was conducted 
according to the methods described by Moffe et al. (38). Processing of samples and mass 
spectrometry were conducted by the Siqueira Laboratory. 
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2.2.5 Scaffold Preparation for Cell Culture and Animal Studies 
Prior to cell culture studies, scaffolds were removed from the sealed plastic containers 
and each scaffold was quenched in 50 mL of 0.1 M glycine (Sigma-Aldrich) for 1 hour to 
remove residual glutaraldehyde. Following quenching, three, 15 minute PBS rinses were 
conducted and the scaffolds were left in PBS at 4°C overnight. For sterilization, scaffolds 
were placed under ultra violet (UV) light for 60 minutes.  
2.2.6 Adhesion Assay 
Scaffolds were punched into circular samples using a 6 mm diameter biopsy punch and 
placed into a 96-well cell culture plate (BD FalconTM, Franklin Lakes, NJ). Cells were 
suspended in serum free Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Carlsbad, 
CA, USA) supplemented with 1% antibiotic-antimicotic (AA) (100 U/mL penicillin, 100 
μg/mL streptomycin and 0.25 μg/mL amphotericin B; Gibco) and seeded at a 
concentration of 2.5 x 10
4
 cells/mL. One hour following seeding, the media was removed 
and wells were rinsed three times with PBS (Gibco) to remove non-adherent cells and 
residual media. Scaffolds were transferred to a 500 μL microcentrifuge tube (Port City 
Diagnostics, Wilmington, NC, USA) and both scaffolds and 96-well plates were stored at 
-80°C until assayed. A cell pellet containing 2 x 10
5
 cells was also frozen at -80°C to 
generate the standard curve. 
Adhesion, measured as cell number attached to the scaffolds, was quantified using the 
CyQUANT® Proliferation Assay Kit (Molecular Probes, Carlsbad, CA, USA). Briefly, 
samples were thawed at room temperature, and 200 μL of CyQUANT® GR dye/cell lysis 
buffer was added to each microcentrifuge tube or well of the 96-well plate for 5 minutes 
at room temperature while subjected to vortexing. Samples were covered in aluminum 
foil during incubation. The supernatant from each sample was collected and transferred to 
a flat-bottom, black 96-well microplate. Serial dilutions of the cell pellet in CyQUANT® 
GR dye/cell lysis buffer were also transferred to the 96-well microplate to create a 
standard curve (Appendix A). Fluorescence of each sample was measured using a Safire
2
 
microplate reader (Tecan, Männedorf, Switzerland) at an excitation wavelength of 480 
nm and an emission wavelength of 520 nm. 
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2.2.7 Proliferation Assay 
Scaffolds were punched into circular samples using a 6 mm diameter biopsy punch and 
placed into a 96-well cell culture plate (BD FalconTM). Human dermal fibroblasts were 
seeded into wells at a density of 3.3 x 10
3
 cells/mL and were cultured for 1, 7, 10 or 14 
days in DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco) and 
1% AA. Split media changes were performed (75 μL) every 2 days. At each experimental 
time point, the media was removed and wells were rinsed three times with PBS to remove 
non-adherent cells and residual media. Scaffolds were transferred to 500 μL 
microcentrifuge tubes and both scaffolds and 96-well plates were stored at -80°C until 
assayed. A cell pellet containing 2 x 10
5
 cells was also frozen at -80°C. The cell number 
at each timepoint was determined using the CyQUANT® proliferation assay kit as 
described in section 2.2.6 and the standard curve is shown in Appendix A. 
2.2.8 Extracellular Matrix Deposition Studies 
Scaffolds were punched into circular samples using a 6 mm diameter biopsy punch and 
placed into a 96-well cell culture plate (BD FalconTM). Human dermal fibroblasts were 
seeded into wells at a density of 3.3 x 10
4
 cells/mL and were cultured for 3 and 7 days in 
DMEM supplemented with 10% FBS (Gibco), 1 % AA and 50 μg/mL ascorbic acid. 
Media was changed every 2 days. At each experimental timepoint, cells were fixed in 4% 
paraformaldehyde (PFA) in PBS for 5 minutes. Three rinses with PBS were conducted 
followed by treatment with 0.1% Triton X-100 in PBS for 5 minutes to permeabilize the 
cell membranes. Cells were rinsed again in PBS three times, followed by blocking with 
1% bovine serum albumin (BSA) in PBS at 4°C overnight. Scaffolds were incubated with 
primary antibodies against fibronectin (sc-8422; Santa Cruz Biotechnology, Dallas, TX, 
USA) diluted at 1:100 in 1% BSA in PBS for one hour at room temperature and were 
rinsed three times with PBS for 5 minutes. Scaffolds were incubated for 90 minutes at 
room temperature with Indodicarbocyanine (Cy5) Goat Anti-Mouse IgG antibody 
(Jackson Immuno Research Laboratories, West Grove, PA, USA) at a 1:200 dilution and 
rhodamine-conjugated phalloidin (Molecular Probes) at a 1:100 dilution. Negative 
controls were prepared without the addition of the primary antibody. Following 
incubation, scaffolds were washed three times for 5 minutes in PBS and mounted on 
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glass coverslips using Vectashield Mounting Medium (Vector Laboratories) containing 
4
’
, 6-diamidino-2-phenylindole (DAPI). Coverslips were sealed with clear nail enamel. 
Samples were analyzed with an Axio Observer Z1 fluorescence microscope (Carl Zeiss) 
using the appropriate filters. Negative controls were imaged to set the threshold values 
for the detection of fluorescence (Appendix B). 
2.2.9 Wound Closure Kinetics Study 
All animal procedures were in compliance with protocols approved by the University 
Council on Animal Care at Western University. Six diabetic (db/db) (B6.BK(D) 
Leprdb/J; 000697) and six wild type (WT) (C57BL/6J; 000664) mice (The Jackson 
Laboratory; Sacramento, CA) were used for experiments.  All mice were age and sex-
matched and were 11 weeks of age at the time of surgery.  Prior to surgery, all mice were 
given 0.05 mg/kg of buprenorphrine as a pre-emptive analgesic. Animals were then 
anaesthetized using isoflurane, fur was removed from the surgical site and povidone-
iodine was used to clean the area. Four full thickness wounds measuring 6 mm in 
diameter were then created using a sterile biopsy punch.   
For wound closure kinetics studies, each wound was assigned one of four treatment 
conditions: empty (control wound), gelatin scaffold, a gelatin scaffold made using 3.3 
μg/mL galectin-3 or a gelatin scaffold made using 6.7 μg/mL galectin-3 (N=6 wounds for 
each treatment group). Treatments were rotated clockwise in each mouse to eliminate 
positional effects on wound healing. Scaffolds measuring 8 mm in diameter and sterilized 
under UV light for 60 minutes were then placed into the wounds. Mice were injected with 
0.05 mg/kg of buprenorphrine again following surgery. On day 17 post-wounding, all 
mice were euthanized using carbon dioxide exposure. Tissue samples of the wounds were 
harvested immediately afterwards and were fixed in 10% neutral buffered formalin 
(Sigma-Aldrich) for 24 hours at 4°C, transferred to 70% ethanol (Commercial Alcohols) 
and were paraffin embedded. Serial 5 μm sections were taken from the center of the 
wounds. To calculate wound closure kinetics, all mice were imaged using a digital 
camera (Canon, Tokyo, Japan) on days 0, 3, 5, 7, 9, 11, 13, 15, and 17.  A ruler was 
included in each image so that the measurements of wound area could be standardized.  
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Image J software (National Institutes of Health) was used to calculate the wounded area 
at each time point (39). 
2.2.10 Investigation of Re-Epithelialization and Macrophage 
Polarization 
All animal procedures were in compliance with protocols approved by the University 
Council on Animal Care at Western University. Six db/db (B6.BK(D)Leprdb/J; 000697) 
and six WT (C57BL/6J; 000664) mice were purchased from The Jackson Laboratory 
(Sacramento, CA). All mice were age-matched and sex-matched and were 12 weeks of 
age at the time of surgery. Prior to surgery, all mice were injected with 0.05 mg/kg of 
buprenorphrine. Animals were then anaesthetized using isoflurane, fur was removed from 
the surgical site and povidone-iodine was used to clean the area. Four full thickness 
wounds measuring 6 mm in diameter were then created using a sterile biopsy punch.   
Each wound was assigned one of four treatment conditions: empty (control wound), 
topical galectin-3 (6.7 μL galectin-3 in sterile saline), gelatin scaffold, or a gelatin 
scaffold containing 6.7 μg/mL galectin-3 (N=6 wounds for each treatment group).  
Scaffolds measuring 8 mm in diameter and disinfected under UV light for 60 minutes 
were then placed into the wounds. Topical galectin-3 was mixed with sterile saline at 6.7 
μg/mL and 10 μL of this solution was added to the wound following the surgery and each 
subsequent day until mice were euthanized. Mice were injected with 0.05 mg/kg of 
buprenorphrine following surgery. Mice were euthanized using carbon dioxide exposure 
on days 5 (N=3 WT mice; N=3 db/db mice) and 7 (N=3 WT mice; N=3 db/db mice) post-
wounding. Tissue samples of the wounds were harvested immediately afterwards and 
were fixed in 10% neutral buffered formalin (Sigma-Aldrich) for 24 hours at 4°C, 
transferred to 70% ethanol (Commercial Alcohols) and were paraffin embedded. Serial 5 
μm sections were taken from the center of the wounds. 
To calculate wound closure kinetics, all mice were imaged on 0, 3, 5, and 7 days. A ruler 
was included in each image so that the measurements of wound area could be 
standardized. Image J software (National Institutes of Health) was used to calculate the 
wounded area at each time point (39). 
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Masson’s Trichrome staining, conducted by the Pathology department within the London 
Health Sciences Centre, was used to visualize collagen deposition and re-
epithelialization. Sections were imaged with a Leica DM100 light microscope (Leica, 
Wetzlar, Germany). Analysis was conducted on Masson’s Trichrome stained sections 
using ImageJ software (National Institutes of Health) to measure the length of the 
epithelial tongue and the thickness of the epithelium (26, 39). 
Immunohistochemical staining for inducible nitric oxide synthase (iNOS) and arginase I 
was performed to visualize M1 and M2 macrophage populations. Sections were 
rehydrated, rinsed with PBS for 5 minutes and subjected to enzymatic antigen retrieval 
for 15 minutes at 37°C. Samples were rinsed again in PBS for 5 minutes at room 
temperature and blocked using 10% horse serum in PBS for 30 minutes at room 
temperature in a humidified chamber. Sections were then incubated in primary goat 
antibodies against arginase I (sc-18354; Santa Cruz Biotechnology) diluted at 1:100 in 
10% horse serum and rabbit antibodies against iNOS (ab3523; Abcam, Cambridge, UK) 
diluted at 1:25 in 10% horse serum overnight at 4°C. Sections were rinsed in PBS and 
incubated with secondary antibodies at a dilution of 1:500 in horse serum for one hour at 
room temperature, while protected from light. Antibodies included an Alexa Fluor 647 
anti-rabbit antibody (Abcam) and an Alexa Fluor 488 anti-goat antibody (Abcam). 
Hoechst 33342 (Trihydrochloride Trihydrate; Thermo Fisher Scientific) was also added 
at a dilution of 1:1000. Sections were rinsed in PBS to remove unbound antibodies and 
were mounted using Immuno-Mount (Thermo Fisher Scientific) mounting medium. 
Coverslips were sealed with clear nail enamel. Sections were imaged using an Axio 
Observer Z1 fluorescence microscope (Carl Zeiss) using the appropriate filters. Negative 
controls were sectioned and stained without the addition of primary antibodies. These 
negative control slides were imaged to set the threshold values for the detection of 
fluorescence (Appendix C). ImageJ software was used to quantify the number of arginase 
I-positive macrophages in the wound bed in WT mice at day 7 (N=3, n=3) (National 
Institutes of Health). 
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2.3 Results 
2.3.1 Influence of Electrospinning Parameters on Fiber Diameter and 
Scaffold Morphology 
To determine the influence of electrospinning parameters on the resulting fiber diameter, 
12 different parameters were assessed. The influence of three different concentrations of 
gelatin, three solution flowrates, and three collector distances on fiber diameter were 
investigated. In order to determine the influence of the flowrate and needle to collector 
distances, these parameters were varied while the concentration of gelatin was held 
constant at 20% weight. Statistical analysis revealed, at each flowrate assessed, there 
were no significant differences in the fiber diameter when the collector distance was 
increased (Figure 2.2; p>0.05). Additionally, at each collector distance, there were no 
significant differences in the fiber diameter when the flowrate was increased (Figure 2.2; 
p>0.05). To determine the influence of gelatin concentration on the resulting fiber 
diameter, both the solution flowrate and the collector distance were held constant while 
the gelatin concentration was increased. As the concentration of gelatin was increased, 
the resulting fiber diameter increased. Scaffolds electrospun using a concentration of 30% 
weight gelatin had a significantly larger mean fiber diameter than fibers electrospun using 
20% weight and 25% weight gelatin (Figure 2.3; p<0.05). Differences in the mean fiber 
diameter between 20% weight and 25% weight gelatin were not statistically significant. 
Increases of fiber diameter corresponding to increases in gelatin concentration were also 
apparent upon observation of the fiber diameter distributions (Figure 2.4G, H, I). 
When 30% weight gelatin was used (Figure 2.4I), the majority of fibers were 500-1500 
nm in diameter. There was a large variation in fiber size, with fibers measuring up to 
4000 nm in diameter. At 25% weight, the majority of the fibers were within range of 300-
500 nm (Figure 2.4H). The distribution of fiber size was even smaller at 20% weight 
gelatin, with the majority of fibers measuring between 100-200 nm (Figure 2.4I). 
To determine whether the differences in fiber diameter were associated with 
morphological changes in the fibers, fiber morphology was assessed in scanning electron 
microscopy (SEM) images taken at each concentration of gelatin. At the 20% weight 
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concentration of gelatin, SEM analysis revealed the presence of beaded fibers in the 
electrospun fiber mat (Figure 2.4A, D). In the fibrous mats electrospun using a 25% 
weight solution of gelatin, SEM showed that the mats contained various web-like and 
ribbon-like fibers (Figure 2.4B and E). Scaffolds electrospun using 30% weight gelatin 
consisted mainly of the ribbon-like fibers, although the relative abundance of cylindrical 
and ribbon-like fibrils was not quantified (Figure 2.4C and F). 
To determine whether increasing the gelatin concentration above 20% weight could 
eliminate beaded fibers, while maintaining fiber diameters within the 100-200 nm range, 
the gelatin concentration was increased to 21% weight and SEM was conducted to 
determine the morphological characteristics as well as measure the resulting mean fiber 
diameter. The resulting mean fiber diameter was 224.6 ± 13.39 nm and SEM revealed 
that there were no beads within the fiber mat (Figure 2.5A). The frequency distribution 
obtained from this sample revealed that fiber diameters ranged from roughly 100-300 nm 
and fibers in the range of 230-250 nm were most frequently measured (Figure 2.5B). 
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Figure 2.2 – Effect of increasing collector distance and flowrate on mean fiber 
diameter: Fiber diameters measured at 9 combinations of flowrate and collector 
distances. The flowrate was varied between 0.1, 0.3 and 0.5 mL/h and the collector 
distance was varied between 6, 10 and 14 cm. The concentration of gelatin was held 
constant at 20% weight. No significant differences in fiber diameter were observed at any 
of the conditions assessed. N=3, n=250, two-way ANOVA, p>0.05. All data is 
represented as mean ± SEM̅. 
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Figure 2.3 – Effect of increasing concentration on mean fiber diameter: Mean fiber 
diameters measured at 20%, 25% and 30% weight gelatin. The flowrate and collector 
distance were held constant at 0.5 mL/h and 10 cm, respectively. Fibers electrospun at a 
concentration of 30% weight gelatin had significantly higher fiber diameters than those 
electrospun at 25% weight and 20% weight gelatin. N=3, n=250, one-way ANOVA, 
Tukey post-test for multiple comparisons, *p <0.05. All data is represented as mean ± 
SEM̅. 
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Figure 2.4 – The effect of increasing concentration on fiber morphology and fiber 
size distribution: A-F: Images of electrospun gelatin nanofibers collected by SEM. Fiber 
mats were electrospun using a flowrate of 0.5 mL/h, collector distance of 10 cm and 
varying gelatin concentrations. A-C: Images were taken at 1000x magnification. Scale 
Bar: 25 μm. D-F: Images were taken at 5000x magnification. Scale Bar: 5 μm. G-I: 
Frequency distribution graph showing the percentage of fiber diameters (from 750 
measurements across N=3 experiments) within each bin range for scaffolds electrospun 
using a flowrate of 0.5 mL/h, a collector distance of 10 cm, and a gelatin concentration of 
20%, 25%, and 30% weight. N=3, n=250. G: Bin size: 20 nm. H: Bin size: 50 nm. I: Bin 
size: 500 nm. At a concentration of 20% weight gelatin, beaded fibers are shown within 
the fiber mat and the majority of fibers measured between 100-200 nm in diameter. At 
25% weight gelatin, both ribbon-like and web-like fibers were detected in the fiber mat.  
The majority of fibers measured between 200-500nm in diameter. At 30% weight gelatin, 
the mat consisted mainly of ribbon-like fibers, the majority of which measured between 
500-1500 nm. 
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Figure 2.5 – Refined scaffold morphology and fiber size distribution: (A) SEM image 
of a scaffold electrospun using a flowrate of 0.5 mL/h, a collector distance of 10 cm, and 
a gelatin concentration of 21% weight. Scale Bar: 15 μm. (B) Frequency distribution 
graph showing the percentage of fiber diameters within each bin range for scaffolds 
electrospun using a flowrate of 0.5 mL/h, a collector distance of 10 cm, and a gelatin 
concentration of 21% weight. N=3, n=250. Bin size: 20 nm. 
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2.3.2 Scaffold Porosity is Sufficient for Cell Growth 
Mercury porosimetry was conducted to evaluate scaffold porosity and to determine 
whether scaffold pore sizes would be sufficient to allow cell infiltration. Analysis 
revealed that scaffolds are 83.08 ± 4.06 % porous and have an average pore diameter of 
1.15 ± 0.77 μm (N=3). A representative graph showing the pore size distribution is 
shown in Figure 2.6. The scaffolds contain pores ranging from 0.1 to 100 μm in size, with 
the majority of the pore diameters are observed within the range of 0.3-0.8 μm and 30-50 
μm.  
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Figure 2.6 – Mercury porosimetry pore size distribution plot: Representative graph of 
pore diameter distribution measured as a function of differential and cumulative intrusion 
volumes. The cumulative pore volume curve shows steeper slopes between 10-100 μm 
and 0.1-1 μm, coinciding with peaks in the log differential intrusion volume. Each log 
differential intrusion value represents the relative quantity of mercury entering pores of a 
specific diameter. Mercury porosimetry was repeated three times (N=3) on different 
batches of scaffolds. 
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2.3.3 Detection of Galectin-3 in Scaffolds 
To ensure the blend electrospinning method resulted in scaffolds containing recombinant 
human galectin-3, mass spectrometry was conducted on crosslinked samples of scaffolds 
electrospun with galectin-3. Table 2 summarizes the findings from the mass spectrometry 
analysis. Four sequences from recombinant human galectin-3 were identified, verifying 
its presence within the scaffolds. Identified sequences were run using the Basic Local 
Alignment Search Tool (BLAST) in the Universal Protein Resource (UniProt) database 
which showed that each detected sequence aligned to a specific sequence contained 
within the CRD of human recombinant galectin-3 and matched with 100% sequence 
identity (Figure 2.7). 
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Table 2: Human recombinant galectin-3 amino acid sequences detected by mass 
spectrometry 
Accession 
Number 
Description Sequences Detected 
Sequence 
Identity (%) 
P17931 
LEG3 HUMAN – 
Galectin-3 Homo Sapiens  
(Human) 
MLITILGTVKPNANR 100 
P17931 
LEG3 HUMAN – 
Galectin-3 Homo Sapiens  
(Human) 
GNDVAFHFNPR 100 
P17931 
LEG3 HUMAN – 
Galectin-3 Homo Sapiens  
(Human) 
IQVLVEPDHFK 
 
100 
P17931 
LEG3 HUMAN – 
Galectin-3 Homo Sapiens 
 (Human) 
VAVNDAHLLQYNHR 100 
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Figure 2.7 – Visualization of detected sequences on recombinant human galectin-3: 
Mass spectrometry was conducted three times for detection of galectin-3. Four peptide 
sequences having 100% alignment with the human recombinant galectin-3 protein 
structure in the carbohydrate recognition domain were detected. (A) 15 amino acid 
sequence of MLITILGTVKPNANR aligns with the protein at amino acid locations 130-
144. (B) 11 amino acid sequence of GNDVAFHFNPR aligns with the protein at amino 
acid locations 152-162. (C) 11 amino acid sequence of IQVLVEPDHFK aligns with the 
protein at amino acid locations 200-210. (D) 14 amino acid sequence of 
VAVNDAHLLQYNHR aligns with the protein at amino acid locations 211-225.            
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2.3.4 Scaffolds Increase the Initial Adhesion of Human Dermal 
Fibroblasts 
Human dermal fibroblasts were seeded onto tissue culture plastic, gelatin scaffolds and 
gelatin/galectin-3 scaffolds (6.7μg/mL). Cells adhered to all surfaces within one hour 
(Figure 2.8). Significantly more cells were detected on gelatin scaffolds relative to the 
tissue culture plastic (N=3, n=3, p<0.01). Similarly, significantly more cells attached to 
gelatin/galectin-3 scaffolds than tissue culture plastic (N=3, n=3, p<0.001).  However, no 
significant differences in cell number were detected between the gelatin and 
gelatin/galectin-3 scaffolds at one hour following seeding (N=3, n=3, p >0.05). 
2.3.5 Scaffolds Support the Proliferation of Human Dermal 
Fibroblasts 
To assess increases in human dermal fibroblast numbers, cell numbers were quantified at 
days 1, 7, 10, and 14 post-seeding. Cell numbers increased over a 14 day period when 
cultured on tissue culture plastic, the gelatin scaffold and the gelatin/galectin-3 scaffold 
(Figure 2.9). There were no significant differences in cell numbers between the three 
conditions at each time point assessed (N=3, n=4, p >0.05). 
2.3.6 Scaffolds Support the Production of Fibronectin by Human 
Dermal Fibroblasts 
Human dermal fibroblasts were cultured on both gelatin scaffolds and gelatin/galectin-3 
scaffolds for up to 7 days to observe whether the scaffolds were able to support secretion 
of fibronectin. Staining of the filamentous actin (red) demonstrated that the cells were 
attached and well spread at days 3 and 7 post-seeding (Figure 2.10). Staining for 
extracellular fibronectin revealed its deposition by fibroblasts on both gelatin and 
gelatin/galectin-3 scaffolds at days 3 and 7 post-seeding (Figure 2.11). Increased 
deposition was seen qualitatively on the scaffolds by day 7 although no observable 
differences in the immunoreactivity for fibronectin was evident between the scaffolds at 
both of the time points examined. 
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Figure 2.8 – Adhesion of human dermal fibroblasts on scaffolds: Human dermal 
fibroblasts were seeded onto tissue culture plastic, gelatin scaffolds and gelatin/galectin-3 
scaffolds (6.7 μg/mL) and left to attach for one hour. At one hour following seeding, cell 
numbers were significantly higher in wells containing the gelatin/galectin-3 scaffolds 
than in tissue culture plastic wells. Cell numbers were also significantly higher in wells 
containing the gelatin scaffolds than in tissue culture plastic wells. N=3, n=3, one-way 
ANOVA, Tukey post-test for multiple comparisons, **p<0.01, ***p<0.001. All data is 
represented as mean ± SEM̅. 
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Figure 2.9 – Proliferation of human dermal fibroblasts on scaffolds:  Human dermal 
fibroblasts were cultured on tissue culture plastic, gelatin scaffolds and gelatin/galectin-3 
scaffolds (6.7 μg/mL) over 14 days. There were no significant differences in the cell 
number between the groups at all time points assessed. N=3, n=4, two-way ANOVA, 
p>0.05. All data is represented as mean ± SEM̅. 
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Figure 2.10 – Visualization of human dermal fibroblast cytoskeleton on scaffolds: 
Human dermal fibroblasts were cultured on tissue culture plastic, gelatin and 
gelatin/galectin-3 scaffolds (6.7μg/mL) over 7 days. Representative images show the cell 
cytoskeleton (red) and cell nuclei (blue) using immunocytochemistry. Human dermal 
fibroblasts cultured on scaffolds show appropriate fibroblast-like morphology and cell 
spreading after 3 days in culture, consistent with the tissue culture plastic controls. Cells 
remain spread along the scaffold surface after 7 days in culture. N=3, n=3, scale bar: 
50μm. 
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Figure 2.11 – Deposition of fibronectin by human dermal fibroblasts on scaffolds: 
Human dermal fibroblasts were cultured on tissue culture plastic, gelatin and 
gelatin/galectin-3 scaffolds (6.7 μg/mL) over 7 days. Representative images show 
fibronectin (green) and cell nuclei (blue) using immunocytochemistry. Fibronectin was 
detected after 3 days on the tissue culture plastic, gelatin and gelatin/galectin-3 scaffolds.  
Fibronectin remained present at 7 days following seeding. There were no observable 
differences in the amount of fibronectin deposited between the scaffolds. N=3, n=3, scale 
bar: 50μm. 
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2.3.7 Gelatin/Galectin-3 Scaffolds Do Not Alter Skin Closure Kinetics 
in Wild Type and Diabetic Mice 
To determine whether gelatin/galectin-3 scaffolds influence wound closure kinetics in 
WT mice, each of the four experimentally created wounds were given a different 
treatment: a gelatin scaffold, a gelatin scaffold loaded with 3.3 μg/mL galectin-3, a 
gelatin scaffold loaded with 6.7 μg/mL galectin-3 or no treatment (left empty). 
Representative images of the wounds for each treatment are shown at day 0, day 9, and 
day 17 in Figure 2.12. Wound closure rates were compared between wounds on days 3, 5, 
7, 9, 11, 13, 15, and 17 following surgery (Figure 2.13). At day 7, statistical analysis 
showed that wounds treated with the gelatin scaffolds had significantly higher wound 
closure than wounds treated with gelatin/galectin-3 scaffolds (6.7 μg/mL) (p<0.05, N=6). 
No statistical differences in wound closure were observed between the treatment groups 
at all other time points assessed (p>0.05, N=6).  
To determine whether gelatin/galectin-3 scaffolds influence wound closure kinetics in an 
impaired model of wound healing, full thickness excisional wounds in db/db mice were 
treated with the same four treatment groups as described for WT mice. Representative 
images of the wounds for each treatment at day 0, day 9, and day 17 are shown in Figure 
2.14. Wound closure was compared between wounds on days 3, 5, 7, 9, 11, 13, 15, and 
17 following surgery (Figure 2.15). Statistical analysis showed that there were no 
significant differences in wound closure between the treatment groups at all time points 
assessed (p>0.05, N=6).  
Masson’s trichrome staining in db/db mice revealed that wounds in each condition were 
completely re-epithelialized by day 17 post-surgery (Figure 2.16). There were no 
observable differences in the thickness of the epithelium or in the amount of collagen in 
each of the conditions assessed. At day 17 in WT mice, the wounds had completely 
closed and the mice had regained hair at the wound site making it difficult to identify the 
original location of the wounds. Therefore, sectioning and staining was not conducted on 
WT mice at day 17.  
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Figure 2.12 – Representative images of the wound area for evaluation of wound 
closure kinetics in WT mice: Full thickness excisional wounds measuring 6 mm in 
diameter were treated with a gelatin scaffold, a gelatin/galectin-3 scaffold (3.3 μg/mL), a 
gelatin/galectin-3 scaffold (6.7 μg/mL), or left empty (control). Representative images of 
the four conditions from one WT mouse are shown at day 0, day 9 and day 17. Wounds 
appear much smaller by day 9 in all treatment conditions and by day 17 wounds achieved 
closure with hair returning to the wound site. N=6, scale bar = 2.5 mm. 
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Figure 2.13 – Wound closure kinetics in vivo for full thickness wounding in WT 
mice: Full thickness excisional wounds measuring 6 mm in diameter were treated with a 
gelatin scaffold, a gelatin/galectin-3 scaffold loaded at 3.3 μg/mL, a gelatin/galectin-3 
scaffold loaded at 6.7 μg/mL, or left empty (control). The percentage of closure relative 
to the original wound was calculated over a 17 day period. There were no significant 
differences between each of the treatment groups and the experimental control (empty 
wound) at all time points assessed (p>0.05). Wound closure increased steadily over the 
17 day period, with all wounds achieving closure by day 17. N=6, two-way ANOVA, 
Tukey post-test for multiple comparisons, p>0.05 between each treatment and the control 
scaffold. Data is represented as mean ± SEM̅. 
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Figure 2.14 – Representative images of the wound area for evaluation of wound 
closure kinetics in db/db mice: Full thickness excisional wounds measuring 6 mm in 
diameter were treated with a gelatin scaffold, a gelatin/galectin-3 scaffold (3.3 μg/mL), a 
gelatin/galectin-3 scaffold (6.7 μg/mL), or left empty (control). Representative images of 
the four treatment conditions from one db/db mouse are shown at day 0, day 9 and day 
17.  Wound size was decreased slightly by day 9 in all treatment conditions. At day 17 
wounds were still visible. N=6, scale bar = 2.5 mm. 
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Figure 2.15 – Wound closure kinetics in vivo for full thickness wounding in db/db 
mice:  Full thickness excisional wounds measuring 6 mm in diameter were treated with a 
gelatin scaffold, a gelatin/galectin-3 scaffold loaded at 3.3 μg/mL, a gelatin/galectin-3 
scaffold loaded at 6.7 μg/mL, or left empty (control).  The percentage of closure relative 
to the original wound was calculated over a 17 day period. There were no significant 
differences between each of the treatment groups and the experimental control (empty 
wound) at all time points assessed (p>0.05).  Wound sizes initially increase in db/db 
mice, with wound closure steadily increasing after day 9. N=6, two-way ANOVA, Tukey 
post-test for multiple comparisons, p >0.05 between each treatment and the control 
scaffold. Data is represented as mean ± SEM̅. 
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Figure 2.16 – Masson’s Trichrome staining at day 17 following in vivo full thickness 
wounding in db/db mice: Representative images of the center of the wound bed for 
db/db mice at 17 days post-wounding. Sections from all six mice were stained and 
analyzed. (A) Empty wound. (B) Wound treated with gelatin scaffold. (C) Wound treated 
with gelatin/galectin-3 scaffold (3.3 μg/mL). (D) Wound treated with gelatin/galectin-3 
scaffold (6.7 μg/mL). Collagen content appeared similar in all conditions assessed at 17 
days post-wounding. Wounds subjected to each treatment condition were fully re-
epithelialized by 17 days post-wounding. N=6, scale bar: 500μm. 
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2.3.8 The Effect of Topical Galectin-3 and Gelatin/Galectin-3 
Scaffolds on Re-Epithelialization in Wild-Type and Diabetic 
Mice 
To determine the effect of gelatin/galectin-3 scaffolds on re-epithelialization at earlier 
time points, full thickness excisional wounds were created in WT and db/db mice and 
received one of 4 treatments: control (empty), topical galectin-3 (6.7 μg/mL), a gelatin 
scaffold, or a gelatin scaffold containing 6.7 μg/mL galectin-3. In WT mice, analysis 
revealed that there were no significant differences in the percentage of wound closure 
across the four treatment groups at 5 and 7 days post-wounding (N=3, p>0.05) (Figure 
2.17A, B). At both days 5 and 7, there were also no significant differences in the 
percentage of re-epithelialization (N=3, p>0.05) (Figure 2.17C, D) or the thickness of the 
epithelium (N=3, p>0.05) between the treatments (Figure 2.17E, F). Masson’s Trichrome 
staining of sections from each treatment group in WT mice at day 5 and day 7 are shown 
in Figure 2.18. 
In the db/db mice, analysis revealed that there were no significant differences in the 
percentage of wound closure across the four treatment groups at 5 and 7 days post 
wounding (N=3, p>0.05) (Figure 2.19A,B). At both days 5 and 7, there were no 
significant differences in the percentage of re-epithelialization (N=3, p>0.05) (Figure 
2.19C, D), or the thickness of the epithelium (N=3, p>0.05) (Figure 2.19E, F). Masson’s 
Trichrome staining of sections from each treatment group in db/db mice at day 5 and day 
7 are shown in Figure 2.20. 
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Figure 2.17 – Wound closure, re-epithelialization and epithelial thickness in WT 
mice: Full thickness excisional wounds measuring 6 mm in diameter were treated with 
topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3 scaffold (6.7 
μg/mL), or left empty (control). (A, B) The percentage of closure relative to the original 
wound was calculated at day 5 (N=3) and day 7 (N=3). There were no significant 
differences in closure between each of the treatment groups at days 5 and 7. N=3, one-
way ANOVA, Tukey post-test for multiple comparisons, p>0.05. (C, D) The percentage 
of re-epithelialization was calculated at day 5 (N=3) and day 7 (N=3). There were no 
significant differences in re-epithelialization between each of the treatment groups at 
days 5 and 7. N=3, one-way ANOVA, Tukey post-test for multiple comparisons, p >0.05. 
(E, F) The thickness of the epithelium was calculated at days 5 (N=3) and day 7 (N=3). 
There were no significant differences in the epithelial thickness between each of the 
treatment groups at days 5 and 7 following wounding. N=3, one-way ANOVA, Tukey 
post-test for multiple comparisons, p>0.05. All data is represented as mean ± SEM̅. 
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Figure 2.18 – Masson’s Trichrome staining following in vivo full thickness wounding 
in WT mice: Full thickness excisional wounds measuring 6 mm in diameter were treated 
with topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3 scaffold (6.7 
μg/mL), or left empty (control). Sections show the wound edge for each condition and the 
epithelial tongue. (A) Images shown of the four treatment conditions are from one mouse 
at day 5 and one mouse at day 7. (B) Images shown of the four treatment conditions are 
from a different mouse at day 5 and a different mouse at day 7 to show the variability 
between mice. S=scaffold, N=3, scale bar: 500μm. 
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Figure 2.19 – Wound closure, re-epithelialization and epithelial thickness in db/db 
mice: Full thickness excisional wounds measuring 6 mm in diameter were treated with 
topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3 scaffold (6.7 
μg/mL), or left empty (control). (A,B) The percentage of closure relative to the original 
wound was calculated at days 5 (N=3) and day 7 (N=3). There were no significant 
differences in closure between each of the treatment groups at days 5 and 7. N=3, one-
way ANOVA, Tukey post-test for multiple comparisons, p>0.05. (C, D) The percentage 
of re-epithelialization was calculated at days 5 (N=3) and day 7 (N=3). There were no 
significant differences in re-epithelialization between each of the treatment groups at 
days 5 and 7. N=3, one-way ANOVA, Tukey post-test for multiple comparisons, p>0.05. 
(E, F) The thickness of the epithelium was calculated at days 5 (N=3) and day 7 (N=3). 
There were no significant differences in the epithelial thickness between each of the 
treatment groups at days 5 and 7. N=3, one-way ANOVA, Tukey post-test for multiple 
comparisons, p>0.05. All data is represented as mean ± SEM̅. 
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Figure 2.20 – Masson’s Trichrome staining following in vivo full thickness wounding 
in db/db mice: Full thickness excisional wounds measuring 6 mm in diameter were 
treated with topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3 
scaffold (6.7 μg/mL), or left empty (control). Sections show the wound edge for each 
condition and the epithelial tongue. (A) Images shown of the four treatment conditions 
are from one mouse at day 5 and one mouse at day 7. (B) Images shown of the four 
treatment conditions are from a different mouse at day 5 and a different mouse at day 7 to 
show the variability between mice. S=scaffold, N=3, scale bar: 500μm. 
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2.3.9 The Influence of Topical Galectin-3 and Gelatin/Galectin-3 
Scaffolds on Macrophage Populations in WT and Diabetic Mice 
During Healing 
To determine the effect of gelatin/galectin-3 scaffolds on re-epithelialization at earlier 
time points, full thickness excisional wounds were created in WT and db/db mice and 
received one of 4 treatments: empty (control), topical galectin-3 (6.7 μg/mL), a gelatin 
scaffold, or a gelatin scaffold containing 6.7 μg/mL galectin-3.  
In the WT mice, there were no observable differences in the amount of arginase I-
positive macrophages across the four treatment groups at day 5 (Figure 2.21). At day 7 
post-surgery, there qualitatively appeared to be more arginase I-positive macrophages in 
the wounds treated with topical galectin-3 (Figure 2.21). Quantification revealed that the 
mean density of arginase I-positive macrophages in the wounds was not statistically 
significant between treatment conditions at day 7 (N=3, n=3, p>0.05) and is shown in 
Figure 2.22. Differences in the number of iNOS-positive macrophages were not observed 
across the four treatment groups at days 5 or 7 (Figure 2.21). 
In the db/db mice, there were no observable differences in the amount of arginase I-
positive macrophages at days 5 and 7 following wounding (Figure 2.23). There were also 
no discernable differences in the amount of iNOS-positive macrophages at day 5 and day 
7 post-wounding (Figure 2.23). 
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Figure 2.21 – Macrophage populations during in vivo full thickness wounding in WT 
mice: Full thickness excisional wounds measuring 6 mm in diameter were treated with 
topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3 scaffold (6.7 
μg/mL), or left empty (control). Sections show the relative amounts of arginase I-positive 
macrophages (green) and iNOS-positive macrophages (red) in the wound bed for each 
treatment condition. Cell nuclei are shown in blue. Images shown are representative of 
sections collected from three separate mice (N=3). (A) At day 5, there are no qualitative 
differences in the amount or localization of arginase I-positive macrophages and iNOS-
positive macrophages. At day 7 there qualitatively appeared to be more arginase I-
positive macrophages in wounds treated with topical galectin-3. At day 7 there are no 
discernable differences in the amount of iNOS-positive macrophages across the four 
treatment conditions. Scale bar: 500μm. (B) Higher magnification images of the areas in 
(A) indicated by grey boxes. Scale bar: 110μm. 
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Figure 2.22 – Quantification of arginase I-positive macrophages within the wound 
bed of WT mice at day 7: Full thickness excisional wounds measuring 6 mm in 
diameter were treated with topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a 
gelatin/galectin-3 scaffold (6.7 μg/mL), or left empty (control). The density of arginase I-
positive macrophages within the wound was determined in WT mice at day 7 following 
wounding using three sections from each of the three mice (N=3, n=3). Although the 
overall density of arginase I-positive macrophages in the wounds was higher in wounds 
treated with topical galectin-3, the differences were not statistically significant. N=3, n=3, 
one-way ANOVA, Tukey post-test for multiple comparisons, p>0.05. All data is 
represented as mean ± SD. 
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Figure 2.23 – Macrophage populations during in vivo full thickness wounding in 
db/db mice: Full thickness excisional wounds measuring 6 mm in diameter were treated 
with topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3 scaffold (6.7 
μg/mL), or left empty (control). Sections show the relative amounts of arginase I-positive 
macrophages (green) and iNOS-positive macrophages (red) in the wound bed for each 
treatment condition. Cell nuclei are shown in blue. Images shown are representative of 
sections collected from three separate mice (N=3). (A) At days 5 and 7, there are no 
qualitative differences in the amount or localization of arginase I-positive macrophages 
and iNOS-positive macrophages in the wound bed. Scale bar: 500μm. (B) Higher 
magnification images of the areas in (A) indicated by grey boxes. Scale bar: 110μm 
112 
 
 
113 
 
 
114 
 
2.4 Discussion 
Chronic skin wounds are problematic as they persist in a pro- inflammatory state, unable 
to progress to the proliferative phase and  restore the barrier function of the epithelium 
(13). Galectin-3 is a protein that has previously been implicated in monocyte migration 
(22), alternative macrophage activation (24), and increased re-epithelialization in corneal 
wounds (25, 40). The use of exogenous galectin-3 in treating full thickness skin wounds 
has yet to be explored. We hypothesized that local delivery of galectin-3 could regulate 
inflammation and increase re-epithelialization in skin healing, ultimately leading to 
wound closure. An electrospun scaffold structure was used to deliver galectin-3 as it 
provides a large surface area for distribution of the protein, for cell adhesion and 
migration, and to protect it from biodegradation (28, 41). The aim of this study was to 
assess the efficacy of an electrospun gelatin scaffold loaded with the matricellular protein 
human galectin-3 for applications in skin healing. 
Type B Bovine gelatin was used as the main structural component of the scaffold. We 
selected gelatin as it is derived from collagen (42), which represents the primary 
structural protein of the dermal extracellular matrix (43). Thus, gelatin provides some 
chemical similarity to the extracellular matrix while reducing cost of scaffold fabrication 
(44). In this thesis, electrospinning was used as the fiber fabrication method. While many 
studies have used collagen as the structural unit in electrospinning, its use is controversial 
as previous reports have demonstrated that collagen loses its tertiary structure following 
electrospinning and fibers generated are typically similar to gelatin in structure (45). 
Gelatin has previously been electrospun by several groups, with results showing good 
biocompatibility of the generated scaffolds, including a study demonstrating increased 
wound closure in a full thickness wound healing model in rats (34-37). Electrospun 
gelatin scaffolds, both alone and in combination with other polymers, have also been 
used with success for the delivery of growth factors and bioactive compounds (46-48). 
Furthermore, the biodegradability of gelatin can be tuned to facilitate protein delivery 
using glutaraldehyde crosslinking, in which aldehyde groups from glutaraldehyde react 
with lysine or hydroxylysine residues to form aldimine linkages (-C=N-) (49, 50). 
Subsequent quenching of the scaffolds in 0.1M glycine is used to block unreacted 
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aldehyde groups (51). Electrospinning of Type B Bovine gelatin was performed using 
40% v/v acetic acid as a solvent. Use of 40% v/v acetic acid has previously been used for 
the electrospinning of collagen, demonstrating bead free fibers in the 100-200 nm range 
along with several other concentrations of this solvent (52, 53). Electrospinning with 
acetic acid is advantageous as it avoids the use of fluoroalcohols, which are highly 
cytotoxic and can cause the loss of tertiary structure and changes in the secondary 
structure of proteins (54).  
The first objective of the thesis was to refine scaffold manufacturing protocols, 
specifically to determine electrospinning parameters that would provide bead-free and 
ribbon-free fibers with diameters measuring within the range of the native extracellular 
matrix (ECM). The polymer solution flowrate, distance between the needle tip and 
collector (collector distance), and the concentration of the polymer have all previously 
been reported to influence the resulting electrospun fiber diameter and morphology (43, 
55, 56). Therefore, to identify an appropriate combination of these parameters, three 
concentrations of gelatin, three flowrates, and three collector distances were tested by 
electrospinning at each set of parameters listed in Table 1.   
Changing the flowrate was not found to significantly influence the resulting mean fiber 
diameter. As a result, a flowrate of 0.5 mL/h was selected for subsequent electrospinning 
as using a higher flowrate decreases the amount of time required for electrospinning and 
decreasing time over which the protein is exposed to the solvent. Similarly, changing the 
collector distance did not influence the resulting mean fiber diameter. A collector 
distance of 10 cm was selected for subsequent electrospinning as this resulted in a wider 
distribution of fibers on the rotating mandrel, creating a larger scaffold surface area, 
without depositing fibers outside of the mandrel. 
Consistent with other studies, increasing the concentration of gelatin resulted in an 
increase in the fiber diameter (37, 51, 57). Although differences in fiber diameter 
resulting from 20% weight and 25% weight gelatin were not considered significant, the 
frequency distribution plot highlighted that when 20% weight gelatin is used, more fibers 
fall within the 100-200 nm range, and there is a narrower distribution of fiber diameters 
116 
 
at this concentration, making it more reflective of the native tissue ECM which has fiber 
diameters within the range of 30-130 nm (44). However, use of 20% weight gelatin 
produced detectable amounts of beaded fibers, which are thought to negatively impact 
cellular interactions with scaffolds (58). Additionally, ribbon-like fibers, which do not 
reflect the morphology of collagen fibrils in the native tissue, were detected at both 25% 
weight and 30% weight gelatin. Therefore, additional experiments were conducted to 
determine whether increasing the gelatin concentration to 21% weight would eliminate 
the fibrous beads, while retaining a small fiber diameter. As expected, the resulting 
scaffolds were free of beaded fibers and did not exhibit ribbon-like fibers. Although the 
fiber diameter was increased, the frequency distribution of the fibers showed that the 
fiber sizes remained within range of collagen fibril sizes found in human tissues (33).  
In the fabrication of electrospun scaffolds, a high porosity is preferable to support cell 
ingrowth and to facilitate the diffusion of waste and nutrients (59). The porosity obtained 
in the refined scaffolds fell within the range of porosities shown in scaffolds electrospun 
using a variety of polymers and electrospinning parameters, ranging from approximately 
60-90% (34, 60, 61). The pore size distribution was also comparable to those seen for 
electrospun gelatin (34, 60). Although the obtained porosity is reasonable, obtaining a 
porosity of 90% has been suggested to be ideal (59). The electrospun scaffolds in this 
study had a low average pore diameter (pore size) of 1.15 μm. Having more pores in the 
50-100 μm range would have also been preferable to coincide with the size of the cells on 
the scaffold and support their infiltration. In fact, scaffolds having pore sizes of 
approximately 100 μm and porosity in the 90% range have been shown to support the 
infiltration of cells from the surface of the scaffold (62). However, it is difficult to obtain 
scaffolds having both pore sizes in this range and fiber sizes in the 100 nm range as 
decreasing fiber size is associated with decreasing pore sizes (63). To overcome this 
problem, several groups have employed strategies whereby substances including salt, or 
simultaneously-electrospun secondary polymers (sacrificial fibers) are deposited within 
the mat during the electrospinning process and are later removed. This process has 
resulted in increased scaffold infiltration by cells (64, 65). 
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Recombinant human galectin-3 was added to the electrospinning solution during scaffold 
fabrication to achieve a final concentration of 6.7 μg/mL. This concentration was chosen 
as it fell within the range used by other groups to achieve effects in vitro. For example, in 
studies in skin, concentrations as low as 1μg/mL have been used to increase keratinocyte 
migration speed (27) and galectin-3 has previously been shown to have a concentration 
dependent effect on monocyte recruitment from 0.001-0.01 μM (66). Additionally, the 
use of 6.3 μg/mL promotes human keratinocyte migration, while use of higher 
concentrations (50 μg/mL) can inhibit migration in vitro (67). Detection of galectin-3 
protein sequences from scaffold samples confirmed that the blend electrospinning method 
could generate scaffolds with galectin-3 dispersed throughout the fibers. The sequences 
identified are located within the protein’s CRD, which is important as this domain is 
required for many of the proteins functions (23-25, 68).  Identification of galectin-3 was 
expected, as several groups have previously used the blend electrospinning method for 
the delivery of matricellular proteins and growth factors (31, 46-48). 
During healing, the granulation tissue is essential in guiding cells into the wound by 
supporting their adhesion and migration (1). Therefore, in order to appropriately mimic 
the extracellular matrix, it is imperative that the scaffolds support the adhesion and 
proliferation of cells (43). The ability of cells to adhere and proliferate on the scaffolds 
was therefore used as a measure of biocompatibility. Dermal fibroblasts were used for the 
study as they interact with and remodel the granulation tissue during healing (1, 14). The 
initial adhesion of human dermal fibroblasts was improved relative to the tissue culture 
plastic in both gelatin and gelatin/galectin-3 scaffolds. This improved adhesion in both 
the gelatin and gelatin/galectin-3 scaffolds likely results from the arginine-glycine-
aspartate (RGD) sequences contained within gelatin, which promote cell adhesion 
through integrin binding (69, 70). The improved adhesion in both scaffolds can also be 
attributed in part to the increased surface area that the scaffolds offer for attachment, 
further promoting cell matrix interactions (32). Over a two-week period, the proliferation 
profile of human dermal fibroblasts on the gelatin and gelatin/galectin-3 scaffolds was 
consistent with that of the tissue culture plastic controls. This finding confirms that both 
the gelatin and gelatin/galectin-3 scaffolds are non-toxic and can support cell growth, 
eliminating concern regarding the use of glutaraldehyde as a crosslinking agent. Our 
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findings are consistent with other groups who have shown consistent proliferation of 
human dermal fibroblasts between gelatin scaffolds and tissue culture plastic controls 
(35, 37). Proliferation on scaffolds that is consistent with culture on tissue culture plastic 
is an important finding, as scaffolds made from other materials, including chitosan and 
polycaprolactone, have demonstrated reduced rates of proliferation (35, 71). 
Surface topography can influence cell responses including adhesion, migration and 
differentiation (72). When cultured on gelatin and gelatin/galectin-3 scaffolds, human 
dermal fibroblasts exhibited a spindle-like morphology and showed alignment of their 
actin filaments. This positive interaction between dermal fibroblasts and gelatin scaffolds 
has also been noted by other groups, who have shown cell spreading and alignment on 
gelatin scaffolds (34, 35, 37). Ensuring that fibroblasts portray a spindle-like morphology 
is significant, as cell spreading is important for cell viability in adherent cell types (73). A 
rounded morphology in fibroblasts is associated with cell detachment (74), which would 
have implied cytotoxicity of the scaffolds (75). Both gelatin and gelatin/galectin-3 
scaffolds also supported the deposition of fibronectin by fibroblasts, indicating dermal 
fibroblasts are able to synthesize extracellular matrix while cultured on the scaffolds. 
Fibronectin deposition by fibroblasts is important during wound healing, as it mediates 
cell adhesion and migration, stimulates collagen deposition, and contributes to wound 
contraction (76).   
Based on the evidence suggesting that the scaffolds were biocompatible in vitro, the 
influence of the scaffolds on wound closure kinetics in mouse models of normal and 
impaired wound healing were investigated. The use of gelatin scaffolds with and without 
the addition of a low and high concentration of galectin-3 did not significantly alter the 
wound closure kinetics in both WT and db/db mice over the 17-day period. At day 17 the 
appearance of cells were consistent with fibroblasts and collagen production in the 
wounds suggest that use of scaffolds did not result in a foreign body response (77). The 
addition of topical galectin-3 also did not increase closure at day 5 or 7, but this does not 
eliminate the possibility of changes early in the inflammatory phase which do not 
manifest in measurable closure changes. Although treating wounds with topical galectin-
3 and scaffolds containing galectin-3 did not significantly increase wound closure 
119 
 
kinetics, this is supported by the finding that wound closure kinetics are not impaired in 
galectin-3 knockout mice, which also show no differences in immune cell infiltration, 
angiogenesis, or fibrotic response (26). Interestingly, use of gelatin scaffolds alone has 
previously been reported to increase wound closure in a full thickness skin model in rats, 
which is in contrast to our findings (34). However, several factors could have contributed 
to the differences in the results obtained by Dubsky et al., including their use of rats as an 
animal model rather than mice, the difference in size of the initial wounds, and their use 
of Tegaderm
TM
 to cover the wounds throughout the study. Dubsky et al. also covered 
control wounds with wetted gauze and the scaffolds were placed over the wound rather 
than being tucked under the surrounding tissue (34).  
During wound healing, keratinocyte proliferation and migration is stimulated by growth 
factors including epidermal growth factor (EGF) (14), resulting in their migration over 
the dermis to restore the epithelial barrier (1). Studies of dermal healing have 
demonstrated that galectin-3 knockout mice exhibit impaired re-epithelialization, which 
manifests in decreased length of the epithelial tongue, and therefore decreased re-
epithelialization at days 2 (27) and 7 (26) post-wounding. This deficient re-
epithelialization was attributed to a migratory defect in keratinocytes caused by aberrant 
EGFR endocytosis and recycling, which cytosolic galectin-3 was shown to mediate 
through binding to ALIX (27). When recombinant human galectin-3 was added to 
wounds of WT mice topically or using a gelatin scaffold, differences in epithelial 
thickness were not quantified at days 5 or 7 post wounding. Similarly, differences were 
not observed in db/db mice at these time points. This result was consistent with previous 
reports showing no defect in epithelial thickness in galectin-3 knockout mice (26, 27).  
Differences in re-epithelialization were also not observed in both WT and db/db mice at 
day 5 and 7 following wounding which was consistent with the finding that exogenous 
galectin-3 was not effective in correcting the defective EGFR endocytosis and recycling 
in galectin-3 knockout mice (27, 50). In contrast, studies of corneal healing have shown 
that exogenous human recombinant galectin-3 can increase re-epithelialization in WT 
mice (25) and in monkey corneal explants (40). However, this increase was suggested to 
be attributed to the modulation of galectin-7 by exogenous galectin-3, as galectin-7 was 
found to accelerate re-epithelialization in galectin-3 knockout mice and mouse embryonic  
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fibroblasts from galectin-3 knockout mice showed reduced levels of galectin-7 (25).  
Studies in skin, which show that gene expression of galectin-7 is not altered at day 7 
following wounding in WT mice, imply that the mechanism suggested to account for 
increased re-epithelialization in the cornea might not apply to the skin (26). This 
discrepancy highlights the issue of the context-specific roles of matricellular proteins 
(78). 
In wound healing, inflammation follows hemostasis, a process during which monocytes 
are recruited to the wound by chemoattractants and differentiate into macrophages (2). 
Macrophages are vital constituents of the wound healing process, mediating wound 
healing through the release of regulatory molecules which is based on their phenotype 
(79).  Classically activated (M1) macrophages produce nitric oxide and secrete pro-
inflammatory cytokines including TNF-α, IL-1, IL-6, and IL-12, while alternatively 
activated macrophages (M2) are implicated in tissue remodeling and secrete TGF-β (80). 
Galectin-3 has previously been implicated in macrophage function (23, 24, 66); therefore 
macrophage populations in WT and db/db mice were investigated after treatment with 
topical galectin-3 and gelatin/galectin-3 scaffolds in order to discern whether exogenous 
human recombinant galectin-3 could increase the number of M2 polarized macrophages.  
Macrophage populations appeared unchanged following treatments in db/db mice at both 
time points. In WT mice, differences were not observed at day 5. At day 7, there 
qualitatively appeared to be more M2 macrophages in wounds treated with topical 
galectin-3, although quantification showed no significant differences in M2 macrophage 
density across the four treatment groups. This result was unexpected as Mackinnon et al. 
reported that bone marrow derived macrophages (BMDMs) from galectin-3 knockout 
mice show a defect in IL-4 and IL-13 M2 macrophage polarization in vivo and in vitro 
(24). In addition they showed that IL-4 and IL-13 can stimulate galectin-3 upregulation 
and release in BMDMs (24). Of note, this study did not test the addition of exogenous 
galectin-3, therefore there is currently no indication as to whether it’s use would be 
sufficient in rescuing the deficient M2 polarization of BMDMs in galectin-3 knockout 
mice. It is also possible that the effect of exogenously added human recombinant 
galectin-3 occurs at earlier time points as the number of galectin-3-positive cells peak at 
one day following wounding in WT mice (78). Or perhaps, exogenous galectin-3 alone is 
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not sufficient in upregulating the expression of surface bound galectin-3, the secretion of 
galectin-3 or upregulating CD98 which are each implicated in the suggested autocrine 
loop that controls M2 activation (24). As human and murine galectin-3 share only 80% 
homology (81), another possibility is that the differences in homology of these species 
contribute to the lack of functionality of exogenous galectin-3 in this feedback loop. 
2.5 Conclusion 
In summary, blend electrospun gelatin/galectin-3 scaffolds have been developed which 
show biocompatibility when tested both in vitro and in vivo. Using human dermal 
fibroblasts, scaffolds increased initial cell adhesion, supported their proliferation over a 
14 day period and supported their production of the extracellular matrix protein 
fibronectin. In vivo, use of the scaffolds in excisional wounds in WT and db/db mice did 
not delay healing or result in a foreign body response at day 17. Use of topical galectin-3 
and gelatin/galectin-3 scaffolds did not affect wound closure, epithelial thickness, or re-
epithelialization in WT and db/db mice, or influence the amount of M1 or M2 
macrophages in WT and db/db mice. Future work should explore the exact pathological 
contexts in which galectin-3 can modulate inflammation. 
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Chapter 3  
3 General Discussion 
3.1 Summary and Final Conclusions 
Objective 1: To develop a scaffold for the delivery of exogenous galectin-3 
Electrospinning parameters that influence fiber formation were investigated, 
demonstrating that altering the flowrate and collector distance did not significantly 
change the resulting electrospun fiber diameters. The largest variable identified was the 
concentration of gelatin in the polymer solution used for electrospinning: at 20% weight 
gelatin, the fiber diameters were smaller, with some fibers showing beads; while at higher 
concentrations, fiber diameters increased significantly and displayed a ribbon-like 
structure. By electrospinning using a polymer solution with 21% weight gelatin, a 
flowrate of 0.5 ml/h and a collector distance of 10 cm, the resulting fibers had diameters 
within the range of extracellular matrix fibers found in dermis. Scaffolds exhibited a high 
porosity, but the average pore diameter was approximately 1μm, which is not conducive 
to cell infiltration. Detection of four sequences from the human galectin-3 carbohydrate 
recognition domain were identified using mass spectroscopy from within a crosslinked 
gelatin/galectin-3 scaffold validating that galectin-3 was incorporated into the gelatin 
scaffolds using the blend electrospinning method. 
Objective 2: To evaluate the biocompatibility of the gelatin/galectin-3 scaffolds in vitro 
using human dermal fibroblasts 
Gelatin and gelatin/galectin-3 scaffolds were shown to increase the adhesion of human 
dermal fibroblasts 1 hour after seeding compared to tissue culture plastic, as well as 
supporting their proliferation over a two-week period. Human dermal fibroblasts also 
spread and elongated on the scaffold fibers, and secreted fibronectin while cultured on 
both the gelatin and gelatin/galectin-3 scaffolds. These findings demonstrated that the 
scaffolds were biocompatible in vitro, with no cytotoxic response evident in the cells. 
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Objective 3: To evaluate the effect of the gelatin/galectin-3 scaffold on wound healing in 
murine models  
a. Assess the influence of the scaffold on wound closure kinetics 
Treatment of wounds with gelatin and gelatin/galectin-3 scaffolds did not alter wound 
closure kinetics in either wild type (WT) or diabetic (db/db) mice.  Collagen production 
and the appearance of cells consistent with fibroblasts in the tissue of db/db mice showed 
that use of the scaffolds did not result in a foreign body response at 17 days. 
b. Compare and contrast the efficacy of local delivery of topical galectin-3 versus 
gelatin/galectin-3 electrospun scaffolds on re-epithelialization and macrophage 
polarization during skin healing. 
Treatment of wounds with either topical galectin-3 or gelatin/galectin-3 scaffolds caused 
no measureable effect on processes associated with re-epithelialization in WT and db/db 
mice at the time points assessed. No significant differences were observed qualitatively in 
the numbers of M1 or M2 macrophages in db/db mice at either time point, or in WT mice 
at day 5 following wounding. At day 7, qualitative assessment suggested that more 
arginase I-positive macrophages were present in wounds treated with topical galectin-3. 
Although quantification revealed that the density of arginase I-positive macrophages was 
higher in these wounds, the results were not significant. Taken together, these findings 
suggest that exogenous galectin-3 is not sufficient for stimulating re-epithelialization in 
skin. However, the role of topical galectin-3 as a therapeutic for M2 macrophage 
polarization requires future investigation. 
3.2 Contributions to the Current State of Knowledge 
3.2.1 Galectin-3 as a Modulator of Re-epithelialization 
Galectin-3 is a matricellular protein that has been implicated in processes associated with 
both the inflammatory and proliferative phases of healing. Studies using experimentally-
created defects in the cornea and skin of knockout mice have identified defects in re-
epithelialization in the absence of galectin-3, in comparison with the same process in WT 
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mice (1-3). Re-epithelialization is an essential process during skin healing, restoring 
barrier function (4). Cao et al. have shown that when applied to knockout mice, human 
recombinant galectin-3 was able to increase re-epithelialization in WT but not knockout 
mice, which was attributed to its effect on the upregulation of galectin-7, a protein shown 
to increase re-epithelialization in both phenotypes (1). In contrast to this research, we 
report here that local delivery of galectin-3 to both WT and db/db mice, does not increase 
re-epithelialization. Although the concentration used in our study (6.7μg/mL) was lower 
than the concentration used in the cornea (10 and 20μg/mL), it was consistent with the 
concentration of 6.3 μg/mL previously used to stimulate keratinocyte migration in vitro 
through laminin 322 binding (5) and with Liu et al., who also showed a pro-migratory 
effect when human recombinant galectin-3 was added at 1μg/mL to keratinocytes from 
WT mice in vitro (2). Our findings, together with the finding that defective epidermal 
growth factor receptor endocytosis (which is controlled via cytosolic galectin-3 rather 
than secreted galectin-3) is the mechanism responsible for impaired re-epithelialization in 
galectin-3 knockout mice in skin (2), suggest that galectin-3 may not be effective in 
promoting re-epithelialization in a recombinant form or when delivered into the 
extracellular microenvironment.  
3.2.2 Galectin-3 as a Modulator of Inflammatory Processes 
With respect to inflammation, galectin-3 typically shows a higher gene and protein 
expression in M2 polarized macrophages (6). It has also been shown to be a 
chemoattractant for monocytes and macrophages (7), and increases the infiltration of 
tumors by M2 macrophages in mice (8). These findings, together with its reported role in 
regulating M2 macrophage polarization (9), suggested that it could represent a legitimate 
therapeutic for mediating inflammation during skin healing in vivo. The findings of this 
thesis do not support a definite connection between the use of exogenous recombinant 
human galectin-3 in dermal wounds in vivo with an associated change in the amount of 
M2 macrophages at days 5 and 7 following wounding. Similar infiltration of M2 
macrophages in the dermal wounds left empty, treated with topical galectin-3, or treated 
with gelatin/galectin-3 scaffolds during healing is consistent with previous studies from 
our laboratory showing that compared to WT mice, galectin-3 knockout mice do not 
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exhibit differences in the abundance of M1 or M2 macrophages during the inflammatory 
phase of healing (3). This is not the first discrepancy in the literature pertaining to the 
role of galectin-3 during inflammation as the finding by Mackinnon et.al that exposure of 
bone marrow derived macrophages to 100 ng/mL lipopolysaccharides (LPS) suppressed 
the expression and secretion of galectin-3 (9) was in contrast to the finding by Novak et 
al. who reported that treatment of  human blood-monocyte derived macrophages exposed 
to 100 ng/mL LPS and 20 ng/mL interferon gamma showed a significant increase in 
galectin-3 expression (6). This discrepancy demonstrates the issue of the context-specific 
roles of the protein (10). Another key issue, in elucidating the role of galectin-3 on 
macrophage polarization, is that its characterization in vitro may not necessarily translate 
in vivo as factors contributing to polarization in vivo, including cell maturation, matrix 
composition and chemoattractants, are often overlooked (11).  
The results of this thesis suggest that in a recombinant form delivered extracellularly, 
there is a lack of evidence to support galectin-3 in increasing re-epithelialization or 
modulating inflammation and that galectin-3 in a recombinant form may not be an 
effective therapeutic for treating chronic skin wounds. However, in order to completely 
dismiss the protein as a therapeutic for this application, further work needs to be 
performed to elucidate the exact pathological contexts in which galectin-3 can modulate 
inflammation. 
3.2.3 Models of Impaired Healing and Galectin-3 
Some groups have suggested that galectin-3 signaling can be either pro-inflammatory or 
anti-inflammatory and depends on the pathophysiological state of the microenvironment 
(12). Considering this hypothesis, it is conceivable that in a chronic wound environment 
in humans, where bacterial colonization can easily occur (13) and where levels of pro-
inflammatory cytokines and reactive oxygen species are exacerbated (14), that the 
delivery of the exogenous galectin-3 would exhibit a modulatory effect on the state of 
inflammation. However, no animal model can accurately mimic the microenvironment 
within a human chronic skin wound, such that the complexity and heterogeneity of these 
wounds can be fully recapitulated (15). This issue is due in part to the multiple factors 
that can contribute to the development of a chronic wound, including infection, 
133 
 
malnutrition, hyperglycemia, and vascular insufficiencies, which are not reflected 
together in animal models (13). Rather, most animal models in mice are monogenic 
models of obesity and diabetes, limiting their clinical translation to humans (16). The 
variability between patients in the cell populations and proteins that are present in the 
wound bed also make translation from animal models difficult (17). As a result, many 
therapeutic targets, including several growth factors, have shown promise for improving 
healing in animal models, but lack efficacy or fail completely in clinical trials (18, 19). 
One such growth factor is vascular endothelial growth factor (VEGF). Pre-clinical studies 
showed that when applied topically, VEGF can accelerate healing in db/db mice (20), yet 
a phase I trial in chronic neuropathic diabetic foot ulcers found no significant differences 
between the reduction in total ulcer surface area in wounds treated with topical VEGF 
relative to placebo-treated wounds after 29, 43, and 84 days (21). The study also failed to 
meet its primary exploratory endpoint of reduced total ulcer surface area at 43 days (21). 
Furthermore, recent clinical studies on platelet derived growth factor, which is the only 
growth factor currently approved by the Food and Drug Administration (22), show that it 
does not significantly improve healing in diabetic foot ulcers relative to those treated with 
an offloading cast, casting doubt on its efficacy (23). 
3.2.4 The Efficacy of Matricellular Proteins as Therapeutics 
Matricellular proteins are non-structural components of the extracellular matrix that are 
normally not expressed in adult tissue, but become upregulated during wound healing and 
pathological processes. Matricellular proteins exhibit tightly regulated expression 
patterns, acting spatially and temporally to control specific cell behaviours, making them 
ideal candidates as therapeutics in wound healing (24). The topical application of 
matricellular proteins has been previously investigated in wound healing in mice in vivo. 
The topical application of exogenous cysteine-rich angiogenic inducer 61 (CCN1) was 
able to reverse the profibrotic phenotype of CCN1 knockin mice that expressed a 
senescence-defective CCN1 mutant, increasing expression of matrix metalloproteinases 
(MMPs) and decreasing expression of transforming growth factor beta (TGF-β) (25). 
Another matricellular protein, angiopoietin-like 4, significantly accelerated wound 
closure relative to saline when applied topically to full thickness excisional splint wounds 
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in ob/ob mice (26). Similarly, the subcutaneous injection of recombinant human galectin-
1 in wounds of WT and streptozotocin-induced diabetic mice also led to accelerated 
closure (27). Our laboratory has shown that scaffolds can also be used to deliver 
matricellular proteins, resulting in effects beneficial to the wound healing process. 
Delivery of persiostin via an electropsun collagen scaffold was able to recover alpha 
smooth muscle actin expression in periostin knockout mice (28). Additionally, the 
delivery of periostin and connective tissue growth factor (CCN2), alone or in 
combination, using an electrospun collagen scaffold significantly accelerated closure in 
full thickness excisional wounds in db/db mice relative to empty controls (Hamilton 
Laboratory, unpublished data). In our study, we show that delivery of exogenous 
galectin-3 either topically, or using an electrospun gelatin scaffold, has shown the lowest 
efficacy in vivo for improving and accelerating the repair of full thickness excisional skin 
wounds.   
3.2.5 Galectin-3 Bioactivity 
An important consideration in assessing the lack of efficacy of both topical and scaffold 
delivery of galectin-3 is the bioactivity of the protein. Post-translational modifications 
can have significant impacts on the biological function of a protein (29). Galectin-3 is 
known to undergo several types of post-translational modifications including cleavage, 
phosphorylation, and acetylation, each having implications on the protein’s function (30). 
For example, galectin-3 can undergo cleavage at multiple sites, including at alanine
62
-
tyrosine
63 
by MMPs 2, 7, 9, and, 13, that results in two distinct peptides and inhibits 
processes requiring N-terminal self-association of the protein (30). The protein can also 
be phosphorylated at tyrosine
79
, tyrosine
107
, and tyrosine
118
 by c-Abl (31), and by casein 
kinase I at serine
6
 (32). Phosphorylation can regulate its binding to ligands, its cellular 
distribution, and its apoptotic activity (30). Additionally, in galectin-3 isolated from rat 
lung, alanine
2
 can be acetylated (33). Therefore, the activity of galectin-3 is dependent on 
many extrinsic microenvironmental factors and it is conceivable that although the protein 
in its recombinant form is able to agglutinate red blood cells (as provided by the 
manufacturer) (34), it may not contain the post translational modifications required for its 
function in triggering M2 macrophage polarization. Other matricellular proteins also 
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exhibit post-translational modification-dependent effects. For example, osteopontin has 
multiple isoforms with differing degrees of phosphorylation that depend on the cell type 
from which it is produced. As a result, the effects of the interaction of this protein with 
cell receptors change depending on its phosphorylation state (35). Therefore, future work 
should focus on determining the exact contexts in which recombinant human galectin-3 
can influence macrophage function. 
3.3 Future Directions 
3.3.1 Improving Scaffold Pore Size 
In addition to a high porosity, large pore sizes are important to ensure the infiltration of 
the scaffolds by cells (36, 37). Co-electrospinning with sacrificial fibers that can be later 
removed in solution is one way to increase the pore area within electrospun scaffolds 
(38). Co-electrospinning of gelatin scaffolds with micrometer sized polyethylene glycol 
fibers has previously been conducted to increase the pore size of scaffolds from 1 μm to 
10-100 μm whereby polyethylene is removed using tert-butanol following crosslinking 
(39). For our purposes, poly ethylene oxide (PEO) would be a good candidate as it is 
highly soluble in water, which would allow removal following gelatin crosslinking (38).  
Klumpp et al. used this method for the electrospinning of a polycaprolactone/collagen 
blended scaffold with PEO as their sacrificial fiber. Following soaking in water, they 
were able to create a scaffold with dense pockets and open sites for cell infiltration (40).  
In vivo they were able to show complete infiltration of their scaffolds after 4 weeks in a 
model of vascularization in rats (40). Using this method to improve porosity in the 
electrospun scaffolds could promote cell infiltration of our scaffolds in vivo during 
excisional healing.  
3.3.2 Establishing Galectin-3 Bioactivity In Vitro and In Vivo 
One of the findings from this thesis relates to the bioactivity of the recombinant human 
galectin-3 protein used in this study. The bioactivity of the protein was quantified by 
R&D systems based on its ability to agglutinate red blood cells. A paper by Hadari et al. 
is referenced, which stated that galectin-3 bioactivity was measured in this manner using 
rabbit erythrocytes (34). Other groups have reported testing galectin-3 bioactivity by 
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treating a Jurkat acute T-cell leukemia cell line with 15 μM of the protein for 6 hours and 
measuring cell viability (6), as the protein has previously been shown to induce apoptosis 
in these cells (41). Our study showed a lack of efficacy of recombinant human galectin-3 
when added to wounds either topically or in combination with a gelatin scaffold. 
Assessing whether the protein had low bioactivity is further compounded by the findings 
from our laboratory that show galectin-3 knockout mice do not display an impairment in 
closure of full thickness excisional wounds (3). Moreover, it is now known that galectin-
3 contains several sites through which activity can be modified by post translational 
modifications, which may be required in order to generate the desired activities 
associated with the protein (30). Therefore, it appears that a well-developed assay for 
detection of recombinant human galectin-3 bioactivity is lacking. As a result, future work 
should be conducted to quantify whether the protein used in the study has bioactivity 
pertaining to macrophage function. As Mackinnon et al. have shown that bone marrow 
derived macrophages from galectin-3 knockout mice exhibit reduced arginase I activity 
from interleukin 4 (IL-4) and IL-13 activation, evaluating the influence of the protein on 
macrophage polarization in vitro using the human monocytic cell line THP-1 might be an 
appropriate area of investigation (9). It would be valuable to identify whether treatment 
with exogenous recombinant human galectin-3 can upregulate M2 macrophage markers, 
including TGF-β and the mannose receptor (MR) (42) in monocytes as well as M1 and 
M2 macrophages. This study would elucidate whether the protein can induce a switch in 
phenotype from M1 to M2 macrophages and if the protein can guide monocytic 
differentiation towards an M2 phenotype. Testing of various concentrations would also 
be appropriate as galectin-3 exhibits concentration dependent effects in vitro and would 
provide a better measure for translation to in vivo studies (7, 43). Once the bioactivity can 
be reproducibly established in vitro, investigation of its role in vivo via topical delivery in 
comparison to untreated wounds could again be explored using a larger number of 
animals to increase the power of the study. Furthermore, elucidating the role of galectin-3 
at earlier time points during healing would be interesting, as the number of galectin-3-
positive cells peak at one day following wounding in WT mice (10). 
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3.4 Limitations 
3.4.1 Animal Model 
Chronic skin wound development is extremely complex and multifactorial, with 
infection, aging, malnutrition and systemic conditions including hyperglycemia and 
vascular insufficiency each contributing to the exacerbation of inflammation (13). In 
addition, these wounds exhibit heterogeneity across patients (13). As a result, no animal 
model exists that can fully recapitulate the multifactorial nature and complexity of  
human chronic wounds (15). The animal model selected in this study was the db/db 
monogenic mouse model of type 2 diabetes. While this model does show prolonged 
inflammation during healing (44), bacterial infection was not considered in the study 
despite playing a contributing role in the delayed healing of human chronic wounds (45). 
Furthermore, although this model has shown impaired wound contraction, it has been 
suggested that this is attributed to the stretching of skin in these mice due to their obesity 
rather than to the disease itself, limiting its translation to chronic wounds in diabetic 
patients (16).  
3.4.2 Calculation of Wound Size and Number of Animals Used in 
Mouse Studies 
In calculating wound closure kinetics, one limitation is the formation of the eschar which 
covers the underlying healing tissue. Calculations of the wound area included the eschar 
present on the surface of the skin. The eschars were not manipulated or removed in any 
of the animals throughout the study and left to fall off naturally as manipulation could 
have disrupted the underlying tissue. As a result, calculated wound areas could have 
appeared larger due to the presence of the eschar, despite the underlying tissue being 
healed. The validity of the mouse studies conducted at earlier time points are also limited 
by the low number of mice used for each condition and at each time point. Including 
more mice in the study would have improved the power of the study, providing stronger 
evidence of the findings.    
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3.5 Final Summary 
This thesis demonstrated that both gelatin and gelatin/galectin-3 scaffolds can be 
electrospun, creating a scaffold with an overall porosity of approximately 83% and 
average pore diameter of approximately 1.15μm. Both gelatin and gelatin/galectin-3 
scaffolds can support the adhesion, deposition of matrix and proliferation of human 
dermal fibroblasts in vitro providing evidence that they are biocompatible. In vivo, both 
gelatin and gelatin/galectin-3 scaffolds did not increase wound closure kinetics, yet did 
not induce a foreign body response in db/db mice at day 17. Treatment of wounds with 
topical galectin-3, gelatin and gelatin/galectin-3 scaffolds did not enhance re-
epithelialization or influence macrophage phenotypes in the wound, demonstrating a lack 
of efficacy for use of galectin-3 in modulating these processes in mice. Future work 
should elucidate the exact pathological instances in which galectin-3 might modulate 
inflammation. 
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Appendices  
Appendix A: Standard curves for the quantification of cell numbers using the 
CyQUANT® Cell Proliferation Assay Kit. 
The fluorescence values were converted into cell numbers using a standard curve 
generated using human dermal fibroblasts. A) Sample standard curve used for cell 
number quantification in adhesion assay. B) Sample standard curve used for cell number 
quantification in proliferation assay. 
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Appendix B: No primary antibody negative control for fibronectin 
immunofluorescence. 
The deposition of the extracellular matrix protein fibronectin was visualized using 
immunocytochemistry. Fibronectin is shown in green and cell nuclei are shown in blue. 
Negative control images were taken of sections that were stained without the use of the 
primary antibody. Negative control images were used to set the threshold values for 
fibronectin fluorescence. Scale bar = 50μm. 
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Appendix C: No primary antibody negative control for arginase I /iNOS 
immunofluorescence. 
The presence of M1 (iNOS
+
) and M2 (arginase I
+
) macrophages was visualized using 
immunocytochemistry. M1 macrophages (iNOS
+
 cells) are shown in red and M2 
macrophages (arginase I
+
 cells) are shown in green. Negative control images were taken 
of sections that were stained without the use of the primary antibodies. Negative control 
images were used to set the threshold values for fibronectin fluorescence. Scale bar = 
500μm. 
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